Anti-porphyromonas gingivalis antibody-drug conjugates and uses thereof
ADCs targeting Porphyromonas gingivalis with a covalent protein binding moiety and self-immolative linker deliver antibiotics effectively, addressing the need for targeted therapies for gingivitis and periodontitis, and associated systemic diseases.
Patent Information
- Application Number
- PCT/US2026/027549
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-02-05
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for therapies that effectively target Porphyromonas gingivalis infections, which can lead to gingivitis and periodontitis, and are associated with various conditions and diseases, including tooth loss and systemic inflammatory diseases.
Development of antibody-drug conjugates (ADCs) that specifically bind to Porphyromonas gingivalis, comprising a covalent protein binding moiety, a self-immolative linker with arginine or lysine, and an antibiotic like sitafloxacin, which are selectively cleaved by gingipains to deliver the antibiotic to the target site.
The ADCs provide targeted delivery of antibiotics to Porphyromonas gingivalis infections, effectively treating conditions such as gingivitis, periodontitis, and associated systemic inflammatory diseases like Alzheimer's disease and heart disease, while minimizing off-target effects.
Smart Images

Figure US2026027549_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No. 58285-0010WO1
[0002] ANTI-PORPHYROMONAS GINGIVALIS ANTIBODY-DRUG CONJUGATES AND USES THEREOF
[0003] This application claims priority to U. S. Provisional Application No. 63 / 802,906 filed on May 9, 2025 and U. S. Provisional Application No. 63 / 976,431 filed on February 5, 2026, the entire contents of all of which are hereby incorporated by reference.
[0004] SEQUENCE LISTING
[0005] This application contains a Sequence Listing that has been submitted electronically as an XML file named 58285-0010WO1.xml. The XML file, created on May 8, 2026, is 106,505 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety.
[0006] FIELD OF THE INVENTION
[0007] Provided herein are antibody drug conjugates (ADCs) comprising an antibody that binds to Porphyromonas gingivalis (P. gingivalis. a linker comprising a covalent protein binding moiety and a self-immolative linker comprising an arginine or lysine; and an antibiotic (e.g., sitafloxacin). Also provided herein are related methods of making said ADCs and methods of using said ADCs, e.g.. in treating a Porphyromonas gingivalis infection in a subject (e.g., human) in need thereof.
[0008] BACKGROUND
[0009] Gingivitis is an inflammation of the gums, usually caused by a bacterial infection. If left untreated, it can become a more serious infection know n as periodontitis. Gingivitis and periodontitis are major causes of tooth loss in adults. Periodontal disease, including P. gingivalis infection, has been implicated in various conditions, disorders or diseases. There exists a need for therapies that target P. gingivalis.
[0010] SUMMARY
[0011] Provided herein are ADCs comprising an antibody that binds to P. gingivalis.- a linker comprising a covalent protein binding moiety and a self-immolative linker comprising anAttorney Docket No. 58285-0010WO1
[0012] arginine or lysine; and an antibiotic (e.g., sitafloxacin). Also provided herein are related linker-payloads and methods of making said ADCs and methods of using said ADCs. As described in the working examples, the ADCs described herein compnse a linker that is selectively cleaved by an arginine or lysine protease, such as the gingipain RgpA, RgpB, or Kgp. This selective cleavage of the linker of the ADC allows for delivery of an antibiotic to a subject in need thereof.
[0013] Provided herein is an ADC comprising: an antibody that binds to Porphyromonas gingivalis', a linker comprising a covalent protein binding moiety and a self-immolative linker comprising an arginine or lysine; and an antibiotic.
[0014] In some instances, the antibody comprises a heavy chain variable region (VH) comprising a VH complementarity determining region (VH CDR) 1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37; and a light chain variable region (VL) comprising aVL CDR1, aVL CDR2, and aVL CDR3 from the sequence of SEQ ID NO:10 or 38. In some instances, the VH CDR1 comprises the sequence of SEQ ID NO:3, the VH CDR2 comprises the sequence of SEQ ID NO:4, the VH CDR3 comprises the sequence of SEQ ID NO:5, the VL CDR1 comprises the sequence of SEQ ID NO:6, the VL CDR2 comprises the sequence of SEQ ID NO:7, and the VL CDR3 comprises the sequence of SEQ ID NO:8. In some instances, the VH comprises the sequence of SEQ ID NO:37 and the VL comprises the sequence of SEQ ID NO:38. In some instances, the VH comprises an amino acid sequence at least 80% identical to the sequence of any one of SEQ ID NOs:29-32 and the VL comprises an amino acid sequence at least 80% identical to the sequence of any one of SEQ ID NOs:33-36. In some instances, the VH comprises the sequence of any one of SEQ ID NOs:29-32 and the VL comprises the sequence of any one of SEQ ID NOs:33-36.
[0015] In some instances, the VH comprises the sequence of SEQ ID NOTO and the VL comprises the sequence of SEQ ID NO:33.
[0016] In some instances, the VH comprises the sequence of SEQ ID NOTO and the VL comprises the sequence of SEQ ID NO:35.
[0017] In some instances, the antibody is a Fab, a diabody, Fab’, F(ab’)2, Fv, a single-chain antibody, bivalent antibody, bispecific antibody, or peptibody.
[0018] In some instances, the antibody is an immunoglobulin comprising a heavy chain (HC) and a light chain (LC). In some instances, the HC comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an amino acid other than lysine at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172,Attorney Docket No. 58285-0010WO1
[0019] optionally wherein the amino acid other than lysine at position 105 as numbered in the sequence of SEQ ID NO: 172 is an alanine.
[0020] In some instances, the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino sequence at least 80% identical to the sequence of SEQ ID NO:263 and the light chain comprises an amino sequence at least 80% identical to the sequence of SEQ ID NO:253.
[0021] In some instances, the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of any one of SEQ ID NOs: 245, 247, 249, 251, 261, 263, 265, and 267, and the light chain comprises the sequence of any one of SEQ ID NOs: 253, 255, 257, and 259.
[0022] In some instances, the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253.
[0023] In some instances, the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:257.
[0024] In some embodiments, the self-immolative linker is:
[0025]
[0026] is the point of attachment to the antibiotic, optionally wherein “-’ isthe point of attachment to an -NEE. -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, and
[0027]
[0028] is the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;
[0029] LAis a bond
[0030]
[0031] O
[0032] I)
[0033] LBis a bond or • -0^, where “** ’ indicates the point of attachment to ( ); ( A j
[0034] ' — ' is selected from phenylene, pyridylene, thiazolylene, and triazolylene;
[0035] Y is absent, -NR3-CH2CH2-NR4-C(O)-, or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein an R7is attached to the pyridylene;
[0036] R1and R2are independently selected from hydrogen and C1-C6 alkyl;Attorney Docket No. 58285-0010WO1
[0037] R3and R4are independently selected from hydrogen and C1-C6 alkyl;
[0038] R5and R6are independently selected from hydrogen and C1-C6 alkyl;
[0039] R7is hydrogen or -(C1-C6 alkylene)P-(O-CH2CH2)r-OR8;
[0040] R8is selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;
[0041] o is 0 or 1;
[0042] p is 0 or 1;
[0043] r is an integer from 1 to 20;
[0044] K is Lysine or Arginine;
[0045] Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, leucine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; and
[0046] is the point of attachment to the covalent protein binding moiety.
[0047] In some embodiments, the self-immolative linker is
[0048]
[0049] In some embodiments, the self-immolative linker is
[0050]
[0051] In some embodiments, the self-immolative linker is
[0052]
[0053] In some embodiments, the self-immolative linker is
[0054]
[0055] In some embodiments, the self-immolative linker isAttorney Docket No. 58285-0010WO1
[0056]
[0057] In some embodiments, K is arginine.
[0058] In some embodiments, K is lysine.
[0059] In some embodiments, Z is valine.
[0060] In some embodiments, Z is serine.
[0061] In some embodiments, the covalent protein binding moiety is selected from the group
[0062] consisting
[0063]
[0064] ; wherein
[0065]
[0066] is the point of attachment to Z of the self-immolative linker;
[0067] indicates the point of attachment to a cysteine residue of the antibody; and
[0068] n and m is an integer from 1-20.
[0069] In some embodiments, the covalent protein binding moiety
[0070]
[0071] , wherein
[0072]
[0073] ” is the point of attachment to Z of the self-immolative linker;
[0074] “*” indicates the point of attachment to a cysteine residue of the antibody; and wherein n is 5.
[0075] In some embodiments, the ADC comprises the structure:
[0076]
[0077] (Formula XIV),
[0078] wherein Q is 1 to 14, wherein the drug is the antibiotic.
[0079] In some embodiments, the ADC comprises the structure:Attorney Docket No. 58285-0010WO1
[0080]
[0081] (Formula XV),
[0082] wherein Q is 1 to 14, wherein the drug is the antibiotic.
[0083] In some embodiments, the ADC comprises the structure:
[0084]
[0085] wherein Q is 1 to 14, wherein the drug is the antibiotic; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0086] In some embodiments, the ADC comprises the structure:
[0087]
[0088] (Formula XVII)
[0089] wherein Q is 1 to 14, wherein the drug is the antibiotic; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0090] In some embodiments, the antibiotic treats a gram-negative bacterial infection.
[0091] In some embodiments, the antibiotic treats a gram-positive bacterial infection.Attorney Docket No. 58285-0010WO1
[0092] In some embodiments, the antibiotic is a fluoroquinolone.
[0093] In some embodiments, the antibiotic is sitafloxacin.
[0094] In some embodiments, the antibiotic is moxifloxacin.
[0095] In some embodiments, the antibiotic is amoxicillin.
[0096] In some embodiments, the antibiotic is metronidazole (MTZ).
[0097] In some embodiments, the ADC comprises:
[0098]
[0099] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5. In some embodiments, the ADC comprises:
[0100]
[0101] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5. In some embodiments, the ADC comprises:
[0102]
[0103] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO1
[0104] In some embodiments, the ADC comprises:
[0105]
[0106] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0107] In some embodiments, the ADC comprises:
[0108]
[0109] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0110] In some embodiments, the ADC comprises:
[0111]
[0112] Q,
[0113] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0114] In some embodiments, the ADC comprises:Attorney Docket No. 58285-0010WO1
[0115]
[0116] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5. In some embodiments, the ADC comprises:
[0117]
[0118] Q,
[0119] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5. In some embodiments, the ADC comprises:
[0120]
[0121] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5. In some embodiments. Q is 1.
[0122] In some embodiments, Q has a value from 3 to 5.Attorney Docket No. 58285-0010WO1
[0123] In some embodiments, the antibiotic is metronidazole, and wherein the ADC
[0124] comprises:
[0125]
[0126] wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0127] In some embodiments, the antibiotic is metronidazole, and wherein the ADC
[0128] comprises:
[0129]
[0130] Q,
[0131] wherein Q is 1 to 14. wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0132] In some embodiments, the antibiotic is metronidazole, and wherein the ADC
[0133] comprises:
[0134]
[0135] Attorney Docket No. 58285-0010WO1
[0136] wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0137] In some embodiments, the antibiotic is amoxicillin, and wherein the ADC comprises:
[0138]
[0139] wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0140] In some embodiments, the antibiotic is sitafloxacin, and wherein the ADC comprises:
[0141]
[0142] Q,
[0143] wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0144] In some embodiments, the antibiotic is moxifloxacin, and wherein the ADC
[0145] comprises:Attorney Docket No. 58285-0010WO1
[0146]
[0147] Q,
[0148] wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0149] In some embodiments, the antibiotic is sitafloxacin, and wherein the ADC comprises:
[0150]
[0151] wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0152] In some embodiments, the antibiotic is metronidazole, and wherein the ADC comprises:
[0153]
[0154] wherein Q is 1 to 14, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 andAttorney Docket No. 58285-0010WO1
[0155] the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0156] In some embodiments, the antibiotic is metronidazole, and wherein the ADC
[0157] comprises:
[0158]
[0159] Q,
[0160] wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0161] In some embodiments, the antibiotic is metronidazole, and wherein the ADC comprises:
[0162]
[0163] wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO1
[0164] In some embodiments, the antibiotic is amoxicillin, and wherein the ADC comprises:
[0165]
[0166] wherein Q is 1 to 14, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0167] In some embodiments, the antibiotic is sitafloxacin, and wherein the ADC comprises:
[0168]
[0169] Q,
[0170] wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0171] In some embodiments, the antibiotic is moxifloxacin, and wherein the ADC
[0172] comprises:Attorney Docket No. 58285-0010WO1
[0173]
[0174] Q,
[0175] wherein Q is 1 to 14, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0176] In some embodiments, the antibiotic is sitafloxacin, and wherein the ADC comprises:
[0177]
[0178] wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0179] Also provided herein is a pharmaceutical composition comprising an ADC described herein, and a pharmaceutically acceptable earner.
[0180] Also described herein is a linker-payload comprising: a linker comprising a covalent protein binding moiety and a self-immolative linker comprising (i) a lysine or arginine, and (ii) a payload, wherein the payload is an antibiotic; wherein
[0181] (a) the self-immolative linker is
[0182]
[0183] Attorney Docket No. 58285-0010WO1
[0184] ' is the point of attachment to the antibiotic, optionally wherein “ isthe point of attachment to an -NH2, -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, and
[0185]
[0186] is the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;
[0187] LAis a bond
[0188]
[0189] LBis a bond
[0190]
[0191] , indicates the point of attachment to; A is selected from phenylene, thiazolylene, and triazolylene;
[0192] Y is absent, -NR3-CH2CH2-NR4-C(O)-, or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein R7is attached to the pyridylene;
[0193] R1and R2are independently selected from hydrogen and C1-C6 alkyl;
[0194] R3and R4are independently selected from hydrogen and C1-C6 alkyl;
[0195] R5and R6are independently selected from hydrogen and C1-C6 alkyl;
[0196] R7is hydrogen or -(C1-C6 alkylene)p-(O-CH2CH2)r-OR8;
[0197] R8is selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;
[0198] o is 0 or 1;
[0199] p is 0 or 1;
[0200] r is an integer from 1 to 20;
[0201] K is Lysine or Arginine;
[0202] Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; and
[0203] is the point of attachment to the covalent protein binding moiety; and
[0204] (b) the covalent protein binding moiety is selected from the group consisting of
[0205]
[0206] is the point of attachment to Z of the self-immolative linker;
[0207] indicates the point of attachment to a cysteine residue of the antibody; and
[0208] n and m is an integer from 1-20.Attorney Docket No. 58285-0010WO1
[0209] Also provided herein is an ADC comprising the foregoing linker-payload. In some instances, the ADC comprises an antibody that binds to P. gingivalis. In some instances, the ADC comprises an antibody described herein.
[0210] Also provided herein is a pharmaceutical composition comprising any one of the foregoing ADCs and a pharmaceutically acceptable carrier.
[0211] Also provided herein are methods of making any one of the foregoing ADCs, the method comprising (a) culturing a cell producing the antibody, (b) isolating the antibody, (c) reducing the isolated antibody, and (c) conjugating the reduced, isolated antibody to the linker comprising the covalent protein binding moiety, the self-immolative linker comprising an arginine or lysine, and an antibiotic; optionally wherein the method further comprises formulating the ADC as a sterile pharmaceutical composition.
[0212] Also provided herein is a method of treating a P. gingivalis infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any one of the foregoing ADCs. In some instances, the subject is a human. In some instances, the administering is intravenously. In some instances, the administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0213] Also provided herein is a method of treating a condition, disorder, or disease associated with a P. gingivalis infection, or symptoms thereof, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any¬ one of the foregoing ADCs. In some instances, the subject is a human. In some instances, the subject has aP. gingivalis infection. In some instances, the administering is intravenously. In some instances, the administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0214] Also provided herein is a method of treating peri-implantitis, periodontal disease, or bone loss associated with periodontal disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any one of the foregoing ADCs. In some instances, the subject is a human. In some instances, the subject has aP. gingivalis infection. In some instances, the administering is intravenously. In some instances, the administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0215] Also provided herein is a method of treating an age-related cognitive disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any one of the foregoing ADCs. In some instances, the age-related cognitive disorder is a dementia. In some instances, the age-related cognitive disorder isAttorney Docket No. 58285-0010WO1
[0216] Alzheimer's disease. In some instances, the subject is a human. In some instances, the subject has aP. gingivalis infection. In some instances, the administering is intravenously. In some instances, the administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0217] Also provided herein is a method of treating a longevity - or age-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of any one of the foregoing ADCs. In some instances, the subject is a human. In some instances, the subject has a P. gingivalis infection. In some instances, the administering is intravenously. In some instances, the administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0218] Also provided herein is a method of treating periodontitis or an associated-systemic inflammatory' disease in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of any' one of the foregoing ADCs. In some instances, the subject has aP. gingivalis infection. In some instances, the associated-systemic inflammatory disease is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease. In some instances, the method further comprises determining that the subject has aP. gingivalis infection. In some instances, the subject is a human. In some instances, the administering is intravenously. In some instances, the administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0219] Also provided herein is a method of treating a systemic inflammatory disease associated with aP. gingivalis infection in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of any one of the foregoing ADCs. In some instances, the subject has aP. gingivalis infection. In some instances, the systemic inflammatory’ disease associated with aP. gingivalis infection is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease. In some instances, the method further comprises determining that the subject has a / ’. gingivalis infection. In some instances, the subject is a human. In some instances, the administering is intravenously. In some instances, the administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0220] Also provided herein is a method of delivering an antibiotic to a subject in need thereof, the method comprising administering to the subject any one of the foregoing ADCs. In some instances, the subject has aP. gingivalis infection. In some instances, the subject is a human. In some instances, the administering is intravenously. In some instances, theAttorney Docket No. 58285-0010WO1
[0221] administering is topically (e.g., an oral topical administration). In some instances, the administering is orally.
[0222] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1A is a representative triple-ToF mass spectrum (ToF MS) of H5-ADC from Example 2 large scale final product with expansions into light (L) and heavy (H) chains.
[0223] FIG. IB is an enlarged version of the heavy chain data of FIG. 1A.
[0224] FIG. 1C is an enlarged version of the light chain data of FIG. 1A.
[0225] FIG. 2 is a representative analytical SEC chromatograph of original antibody H5 after initial freeze-thaw and storage at 4 °C > 2 weeks prior to freeze-thaw studies. Detection at 280 nm; SEC solvent used 200 mM potassium phosphate with 250 mM potassium chloride at pH 6.95 over 10 minutes.
[0226] FIG. 3 is a representative analytical SEC chromatograph of H5-ADC from Example 2 large scale final product. Detection at 280 nm; SEC solvent used 200 mM potassium phosphate with 250 mM potassium chloride at pH 6.95 over 10 minutes.
[0227] FIG. 4 depicts a Coomassie blue stained gel of H5 and H5-ADC under non-reducing condition, 4-12% Bis-Tris gel, 200V, 25 minutes. M is PageRuler Plus protein ladder.
[0228] FIGs. 5A-5D is ToF MS spectrum of H5 (deglycosylated and deglycosylated / reduced) in initial state (#0) and after the 4thfreeze-thaw cycle (#4).
[0229] FIGs. 6A-6D is ToF MS spectrum of H5-ADC (deglycosylated and deglycosylated / reduced) in initial state (#0) and after the 4thfreeze-thaw cycle (#4).
[0230] FIG. 7A is a graph depicting the linker-antibiotic peak area (y-axis) at the indicated concentration of 3326-01 linker-antibiotic (x-axis) incubated with lysyl endopeptidase. From top to bottom, each line is: (i) no enzyme, (ii) 25 ng / mL lysyl endopeptidase, (iii) 50 ng / mL lysyl endopeptidase, (iv) 100 ng / mL lysyl endopeptidase, and (v) 200 ng / mL lysyl endopeptidase.
[0231] FIG. 7B is a graph depicting the sitafloxacin peak area (y-axis) at the indicated concentration of 3326-01 linker-antibiotic (x-axis) incubated with lysyl endopeptidase, for the experiment of FIG. 7A. From top to bottom, each line is: (i) 200 ng / mL lysyl endopeptidase, (ii) 100 ng / mL lysyl endopeptidase, (iii) 50 ng / mL lysyl endopeptidase, (iv) 25 ng / mL lysyl endopeptidase, and (v) no enzyme.
[0232] FIG. 7C is a graph depicting the sitafloxacin calibration curve used to quantitate the sitafloxacin generated in samples based on the peak areas in FIG. 7B.Attorney Docket No. 58285-0010WO1
[0233] FIG. 8A is a graph depicting the linker-antibiotic peak area (y-axis) at the indicated concentration of 3361-01 linker-antibiotic (x-axis) incubated with lysyl endopeptidase. From top to bottom, each line is: (i) no enzyme, (ii) 25 ng / mL lysyl endopeptidase, (iii) 50 ng / mL lysyl endopeptidase, (iv) 100 ng / mL lysyl endopeptidase, and (v) 200 ng / mL lysyl endopeptidase.
[0234] FIG. 8B is a graph depicting the sitafloxacin peak area (y-axis) at the indicated concentration of 3361-01 linker-antibiotic (x-axis) incubated with lysyl endopeptidase, for the experiment of FIG. 8A. From top to bottom, each line is: (i) 200 ng / mL lysyl endopeptidase, (ii) 100 ng / mL lysyl endopeptidase, (iii) 50 ng / mL lysyl endopeptidase, (iv) 25 ng / mL lysyl endopeptidase, and (v) no enzyme.
[0235] FIG.8C is a graph depicting the sitafloxacin calibration curve used to quantitate the sitafloxacin generated in samples based on the peak areas in FIG. 8B.
[0236] FIG.9 is a graph depicting relative fluorescence unit (RFU) over time (minutes) for no kallikrein 13 enzyme (bottom plot), 750 ng / mL kallikrein 13 enzyme (top plot), or 375 ng / mL kallikrein 13 (middle plot) enzyme incubated with control peptide.
[0237] FIG. 10A is a graph depicting sitafloxacin peaks at the indicated sitafloxacin concentration.
[0238] FIG. 10B is a graph depicting sitafloxacin peak areas (y-axis) for the indicated ADC H5-CUR-3326-01 concentrations in the presence of the indicated concentrations of kallikrein 14. Lines from top to bottom: 3000 ng / mL kallikrein 13, 1500 ng / mL kallikrein 13, 750 ng / mL kallikrein 13, 375 ng / mL kallikrein 13, and no enzyme, respectively.
[0239] FIG.11A is a graph depicting sitafloxacin peaks at the indicated sitafloxacin concentration.
[0240] FIG. 1 IB is a graph depicting sitafloxacin peak areas (y-axis) for the indicated ADC H5-CUR-3326-01 concentrations in the presence of the indicated concentrations of kallikrein 14. Lines from top to bottom: 3000 ng / mL kallikrein 13, 1500 ng / mL kallikrein 13, 750 ng / mL kallikrein 13, 375 ng / mL kallikrein 13, and no enzyme, respectively.
[0241] FIG. 12A is a graph depicting the Fabfluor spot intensity sum / cell area (y-axis) at the indicated time point (x-axis) for anti-CD71 at the indicated concentrations. Lines from top to bottom at final timepoint: 5000 ng / mL, 2500 ng / mL, 1250 ng / mL, 625 ng / mL, 312.5 ng / mL, 156.25 ng / mL, 78.13 ng / mL, 39.06 ng / mL, 19.53 ng / mL, 9.77 ng / mL, and untreated, respectively.
[0242] FIG. 12B is a graph depicting the area under curve (y-axis) for internalization of anti-CD71 antibody into primary gingivalis keritinocytes at the indicated concentrations (x-axis).Attomey Docket No. 58285-0010W01
[0243] FIG. 13A is a graph depicting the Fabfluor spot intensity sum / cell area (y-axis) at the indicated time point (x-axis) for cetuximab at the indicated concentrations. Lines from top to bottom at final timepoint: 5000 ng / mL, 2500 ng / mL, 1250 ng / mL, 625 ng / mL, 312.5 ng / mL, 156.25 ng / mL, 78.13 ng / mL, 39.06 ng / mL, 19.53 ng / mL, 9.77 ng / mL, and untreated, respectively.
[0244] FIG. 13B is a graph depicting the area under curve (y-axis) for internalization of cetuximab antibody into primary gingivalis keritinocytes at the indicated concentrations (x-axis).
[0245] FIG. 14A is a graph depicting the Fabfluor spot intensity sum / cell area (y-axis) at the indicated time point (x-axis) for human IgGl isotype at the indicated concentrations. Lines from top to bottom at final timepoint: 5000 ng / mL, 2500 ng / mL, 1250 ng / mL, 625 ng / mL, 312.5 ng / mL, 156.25 ng / mL, 78.13 ng / mL, 39.06 ng / mL, 19.53 ng / mL, 9.77 ng / mL, and untreated, respectively.
[0246] FIG. 14B is a graph depicting the area under curve (y-axis) for internalization of human IgGl isotype antibody into primary gingivalis keritinocytes at the indicated concentrations (x-axis).
[0247] FIG. 15A is a graph depicting the Fabfluor spot intensity sum / cell area (y-axis) at the indicated time point (x-axis) for H5 antibody at the indicated concentrations. Lines from top to bottom at final timepoint: 5000 ng / mL, 2500 ng / mL, 1250 ng / mL, 625 ng / mL, 312.5 ng / mL. 156.25 ng / mL. 78.13 ng / mL, 39.06 ng / mL, 19.53 ng / mL, 9.77 ng / mL, and untreated, respectively.
[0248] FIG. 15B is a graph depicting the area under curve (y-axis) for internalization of H5 antibody into primary gingivalis keritinocytes at the indicated concentrations (x-axis).
[0249] FIG. 16A is a graph depicting the Fabfluor spot intensity sum / cell area (y-axis) at the indicated time point (x-axis) for H5-CUR-3326-01 ADC at the indicated concentrations. Lines from top to bottom at final timepoint: 5000 ng / mL, 2500 ng / mL, 1250 ng / mL, 625 ng / mL, 312.5 ng / mL, 156.25 ng / mL, 78.13 ng / mL, 39.06 ng / mL, 19.53 ng / mL, 9.77 ng / mL, and untreated, respectively.
[0250] FIG. 16B is a graph depicting the area under curve (y-axis) for internalization of H5-CUR-3326-01 ADC into primary gingivalis keritinocytes at the indicated concentrations (x-axis).
[0251] FIG. 17 is a graph depicting the area under curve (y-axis) for internalization of the indicated antibodies into primary gingivalis keritinocytes at the indicated concentrations (x-Attorney Docket No. 58285-0010WO1
[0252] axis). For each concentration, the bars are (from left to right): anti-CD71, cetuximab, H5, H5-CUR3326-01, and human IgGl isotype control, respectively.
[0253] FIG. 18 is a scheme depicting the preparation of the antibody-metronidazole conjugate.
[0254] FIG. 19A is a representative triple-ToF mass spectrum (ToF MS) of the small scale metronidazole H5-ADC from with expansions into light (L) and heavy (H) chains.
[0255] FIG. 19B is an enlarged version of the heavy chain data of FIG. 19A.
[0256] FIG. 19C is an enlarged version of the light chain data of FIG. 19A.
[0257] FIG. 20A is a representative triple-ToF mass spectrum (ToF MS) of the large scale metronidazole H5-ADC from with expansions into light (L) and heavy (H) chains.
[0258] FIG. 20B is an enlarged version of the heavy chain data of FIG. 20A.
[0259] FIG. 20C is an enlarged version of the light chain data of FIG. 20A.
[0260] FIG. 21A is a representative analytical SEC chromatograph of original antibody H5 after initial freeze-thaw and storage prior to freeze-thaw studies.
[0261] FIG. 21B is a representative analytical SEC chromatograph of metronidazole H5-ADC large scale final product.
[0262] FIG. 22 is an analytical SEC chromatograph of metronidazole H5-ADC after 0-4 freeze-thaw cycles.
[0263] FIG. 23A is a chromatograph of H5 antibody.
[0264] FIG. 23B is an expanded view of the plot in FIG. 23 A.
[0265] FIG. 24A is a chromatograph of antibody-metronidazole conjugate.
[0266] FIG. 24B is an expanded view of the plot in FIG. 23 A.
[0267] FIG. 25A is a chromatograph of pay load linker.
[0268] FIG. 25B is a chromatograph of antibody-metronidazole conjugate.
[0269] FIG. 25C is a standard calibration curve for converting chromatographic peak areas to analyte concentrations.
[0270] FIG. 26A is a substrate peak value table comparing peak values for the negative control and 50 nM RgpB6H at different linker concentrations and 100 pM metronidazole.
[0271] FIG. 26B is a plot of substrate peaks in samples lacking enzyme vs. linker concentration at different times.
[0272] FIG. 26C is a plot of substrate peaks in samples including 50 nM RgpB6H vs. linker concentration at different times.Attorney Docket No. 58285-0010WO1
[0273] FIG. 27 A is a product peak value table comparing peak values for the negative control and 50 nM RgpB6H at different linker concentrations and 100 pM metronidazole; and metronidazole concentrations observed for the negative control and 50 nM RgpB6H at different linker concentrations and 100 pM metronidazole.
[0274] FIG. 27B is a metronidazole calibration curve.
[0275] FIG. 27C is a plot showing metronidazole concentration in samples including 50 nM RgpB6H vs. linker concentration at different times.
[0276] FIG. 28A is a peak value table showing the linker peaks observed in wells lacking enzyme, wells treated with 25 nM RgpB6H, and wells treated with 50 nM RgpB6H.
[0277] FIG. 28B is a bar graph depicting the data in FIG. 28A.
[0278] FIG. 29A is a peak value table showing the metronidazole peaks observed in wells lacking enzyme, wells treated with 25 nM RgpB6H, and wells treated with 50 nM RgpB6H.
[0279] FIGS. 29B is a metronidazole concentration table showing the concentration of metronidazole in wells lacking enzyme, wells treated with 25 nM RgpB6H, and wells treated with 50 nM RgpB6H after 30 minutes.
[0280] FIGS. 29C is a metronidazole concentration table showing the concentration of metronidazole in wells lacking enzy me, wells treated with 25 nM RgpB6H, and wells treated with 50 nM RgpB6H.
[0281] FIG. 29D is a bar graph depicting the data in FIG. 29 A.
[0282] DETAILED DESCRIPTION
[0283] The present disclosure relates to ADCs that selectively bind to P. gingivalis gingipain and deliver via proteolytic cleavage an antibiotic. ADCs provided herein comprise an antibody that binds to P. gingivalis,' a linker comprising a covalent protein binding moiety and a self-immolative linker comprising an arginine or lysine; and an antibiotic (e.g, sitafloxacin).
[0284] As shown in the working examples herein, the ADCs described herein are selectively cleaved by arginine- or lysine-specific proteases. In this regard, the ADCs described herein are designed such that when delivered to the oral cavity, the linker of the ADC is selectively cleaved by the gingipain antibody target — which is an arginine or lysine-specific protease. In this regard, saliva contains proteases, including kallikreins and lactoferrin, which cleave at arginine or lysine residues. Gingipains, like many proteases, do not require a highly specific amino acid sequence as a target for cleavage. An arginine or lysine residue in a region of aAttorney Docket No. 58285-0010WO1
[0285] protein that is sterically accessible to the protease is the basic requirement. The specific amino acid preferences around the Arg / Lys and a putative optimal target sequence do not seem to be reported for any gingipain. Three gingipains exist. RgpA and RgpB target arginine, while Kgp targets lysine.
[0286] Kallikreins are a family of proteases, most of whom, like gingipains, require an arginine or lysine as the essential feature of a target sequence. Ten out of the fifteen known human kallikreins have been found to be expressed in salivary gland tissue. Lactoferrin is a multifunctional enzyme also found in saliva that has proteolytic activity and cleaves at arginine-rich sequences.
[0287] Also provided herein are compositions (e.g., pharmaceutical compositions) comprising said ADCs, methods of making said ADCs, and methods of using said ADCs, e.g., in treating aPorphyromonas gingivalis infection in a subject (e.g., human) in need thereof, treating a condition, disorder, or disease associated with aP. gingivalis infection, or symptoms thereof in a subject (e.g., human) in need thereof, and delivering an antibiotic to a subject (e.g., human) in need thereof.
[0288] ANTI-PORPHYROMONAS GINGIVALIS ANTIBODIES
[0289] The ADCs described herein comprise an antibody that binds to Porphyromonas gingivalis. Exemplary antibodies are described in Table 1 and Table 2, below. Table 1 provides the CDRs, VH, VL, heavy chain (HC), and light chain (LC) sequences for antibody KB001. Table 2 provides the VH, VL, HC, and LC sequences for humanized variants of KB001, H1-H16, and K222A mutants thereof. H1-H16 share the same CDRs according to the Kabat, IMGT, Chothia, AbM, and Contact designations as antibody KB001.
[0290] The antibodies can comprise the VH CDR1, VH CDR2. and VH CDR3 of KB001 or a humanized variant thereof (e.g., H5) according to the Kabat definition, or an alternate CDR definition such as, but not limited to, the IMGT definition, the Chothia definition, the AbM CDR definition, or the contact definition. See Table 1. These antibodies may include zero, one, two, or three substitutions in VH CDR1 and / or VH CDR2 and / or VH CDR3 of KB001 or a humanized variant thereof (e.g., H5). In some embodiments, the antibodies further comprise the VL CDR1, VL CDR2, and VL CDR3 of KB001 or a humanized variant thereof (e.g., H5) according to the Kabat definition, or an alternate CDR definition such as, but not limited to, the IMGT definition, the Chothia definition, the AbM CDR definition, or the contact definition. See Table 1. These antibodies may include zero, one, two, or threeAttorney Docket No. 58285-0010WO1
[0291] substitutions in VL CDR1 and / or VL CDR2 and / or VL CDR3 of KB001 or a humanized variant thereof (e.g., H5).
[0292] In some instances, the antibody encompasses the VH CDR1, VH CDR2, and VH CDR3 and the VL CDR1, VL CDR2, and VL CDR3 of KB001 (see Table 1) or a humanized variant thereof (see, e.g., Table 2; e.g., H5 or H5-K222A). In some instances, the antibody comprises the VH CDR1, VH CDR2, and VH CDR3 and the VL CDR 1, VL CDR2, and VL CDR3 of KB001 (see Table 1). In some instances, the antibody comprises the VH CDRL VH CDR2, and VH CDR3 and the VL CDR 1, VL CDR2, and VL CDR3 of H5 (see Table 2). In some instances, the antibody comprises the VH CDR1, VH CDR2, and VH CDR3 and the VL CDR 1, VL CDR2, and VL CDR3 of H7 (see Table 2).
[0293] In some instance, the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9; and a VL comprising a VL CDRL a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO: 10.
[0294] In some instance, the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO: 37; and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO: 38.
[0295] In some instances, the antibody comprises a VH comprising VH CDR1, VH CDR2, and VH CDR3 of H5 (see Table 2). In some instances, the antibody comprises a VL comprising VL CDR1, VL CDR2, and VL CDR3 of H5 (see Table 2). In some instances, the antibody comprises a VH comprising VH CDR1, VH CDR2, and VH CDR3 of H5 (see Table 2) and a VL comprising VL CDR1, VL CDR2, and VL CDR3 of H5 (see Table 2). In some instances, the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO: 30; and aVL comprising aVL CDR1, aVL CDR2, and a VL CDR3 from the sequence of SEQ ID NO: 33. In some instances, the antibody comprises a VH comprising the VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NOs: 3-5, respectively, and a VL comprising the VL CDR1, VL CDR2, and VL CDR3 set forth in SEQ ID NOs: 6-8, respectively. In some instances, the antibody comprises a VH comprising the VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NOs: 11-13, respectively, and a VL comprising the VL CDRL VL CDR2. and VL CDR3 set forth in SEQ ID NOs: 14, 15, and 8, respectively. In some instances, the antibody comprises a VH comprising the VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NOs: 16-18, respectively, and a VL comprising the VL CDR1, VL CDR2, and VL CDR3 set forth in SEQ ID NOs: 6-8. respectively. In some instances, the antibody comprises a VH comprising the VH CDRL VH CDR2, and VH CDR3 set forth in SEQ ID NOs: 3, 19, 18, respectively, and aAttorney Docket No. 58285-0010WO1
[0296] VL comprising the VL CDR1, VL CDR2, and VL CDR3 set forth in SEQ ID NOs: 6-8, respectively. In some instances, the antibody comprises a VH comprising the VH CDR1, VH CDR2, and VH CDR3 set forth in SEQ ID NOs: 20-22, respectively, and a VL comprising the VL CDR1, VL CDR2, and VL CDR3 set forth in SEQ ID NOs: 23-25, respectively.
[0297] In some instances, the antibody has, e.g., 1, 2, or 3 substitutions within one or more (i.e., 1, 2, 3, 4, 5, or 6) of the six CDRs ofKBOOl (see Table 1) or a humanized variant thereof (see, e.g.. Table 2; e.g., H5).
[0298] In certain embodiments, the antibody comprises an amino acid sequence having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to the amino acid sequence set forth iany one of SEQ ID NOs:29-32. In certain embodiments, the antibody comprises an amino acid sequence having one or more (e.g., 1. 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to the amino acid sequence set forth in any one of SEQ ID NOs:256, 261, 247, 263, 249, 265, 251, and 267. In certain embodiments, the antibody comprises a VH comprising the VH CDR1, VH CDR2. and VH CDR3 of H5 (see Table 2, e.g., according to the Kabat definition, i.e., the amino acid sequences set forth in SEQ ID NOs: 3-5, respectively), wherein the VH comprises an amino acid sequence having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to the amino acid sequence set forth in SEQ ID NO:30. In some embodiments, the antibody comprises a heavy chain comprising the VH CDR1. VH CDR2, and VH CDR3 of H5 (see Table 2, e.g.. according to the Kabat definition, i.e., the amino acid sequences set forth in SEQ ID NOs: 3-5, respectively), wherein the heavy chain comprises an amino acid sequence having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to the amino acid sequence set forth in SEQ ID NO:247 or 253. In certain embodiments, the antibody comprises an amino acid sequence having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to the amino acid sequence set forth in any one of SEQ ID NOs:33-36. In certain embodiments, the antibody comprises an amino acid sequence having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to the amino acid sequence set forth in any one of SEQ ID NOs:253, 255, 257, and 259. In certain embodiments, the antibody comprises a VL comprising the VL CDR1, VL CDR2, and VL CDR3 of H5 (see Table 2, e.g., according to the Kabat definition, i.e., the amino acid sequences set forth in SEQ ID NOs: 6-8, respectively), wherein the VL comprises an amino acid sequence having one or more (e.g.. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to theAttorney Docket No. 58285-0010WO1
[0299] amino acid sequence set forth in SEQ ID NOs:33. In some embodiments, the antibody comprises a light chain comprising the VL CDR1, VL CDR2, and VL CDR3 of H5 (see Table 2, e.g., according to the Kabat definition, i.e., the amino acid sequences set forth in SEQ ID NOs: 6-8, respectively), wherein the light chain comprises an amino acid sequence having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10) amino acid substitutions, additions, and / or deletions relative to the amino acid sequence set forth in SEQ ID NO:253. In some instances, the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an amino acid other than lysine at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172. In some instances, the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an alanine (instead of a lysine) at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172.
[0300] In some instances, the antibody comprises a VH comprising the VH CDRs 1-3 of SEQ ID NOs:3-5, respectively. In some instances, the antibody comprises a VL comprising the VL CDRs 1-3 of SEQ ID NOs:6-8, respectively. In some instances, the antibody comprises a VH comprising the VH CDRs 1-3 of SEQ ID NOs:3-5, respectively, and a VL comprising the VL CDRs 1-3 of SEQ ID NOs:6-8, respectively.
[0301] In some instances, the antibody comprises the VH CDRs 1-3 and the VL CDRs 1-3 (e.g., according to Kabat) of KB001 and comprises a VH having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:30. In some instances, the antibody comprises the VH CDRs 1-3 and the VL CDRs 1-3 (e.g., according to Kabat) of KB001 and comprises a VL having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:33. In some instances, the antibody comprises the VH CDRs 1-3 and the VL CDRs 1-3 (e.g., according to Kabat) of KB001 and comprises a VH having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:30 and a VL having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, atAttorney Docket No. 58285-0010WO1
[0302] least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:33.
[0303] In some instances, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 30. In some instances, the antibody comprises a VL comprising the amino acid sequence of SEQ ID NO: 33. In some instances, the antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 30 and a VL comprising the amino acid sequence of SEQ ID NO:33. In some instances, the antibody comprises a VH consisting of the amino acid sequence of SEQ ID NO:30 and a VL consisting of the amino acid sequence of SEQ ID NO 33.
[0304] In some instances, the antibody comprises the VH CDRs 1-3 of H5 (see Table 2, e.g., SEQ ID NOs:3-5) and a heavy chain having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:247 or 263. In some instances, the antibody comprises the VL CDRs of H5 (see Table 2, e.g., SEQ ID NOs:6-8) and a light chain having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:253. In some instances, the antibody comprises the VH CDRs 1-3 of H5 (see Table 2, e.g., SEQ ID NOs:3-5) and a heavy chain having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity7to the amino acid sequence of SEQ ID NO:247 or 263, and the antibody comprises the VL CDRs of H5 (see Table 2, e.g., SEQ ID NOs:6-8) and a light chain having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:253. In some instances, the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an amino acid other than lysine at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172. In some instances, the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an alanine (instead of aAttorney Docket No. 58285-0010WO1
[0305] lysine) at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172.
[0306] In some instances, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:247. In some instances, the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:253. In some instances, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:247 and a light chain comprising the amino acid sequence of SEQ ID NO:253. In some instances, the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO:247 and a light chain consisting of the amino acid sequence of SEQ ID NO:253.
[0307] In some instances, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:263. In some instances, the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 253. In some instances, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 263 and a light chain comprising the amino acid sequence of SEQ ID NO:253. In some instances, the antibody comprises a heavy chain consisting of the amino acid sequence of SEQ ID NO: 263 and a light chain consisting of the amino acid sequence of SEQ ID NO:253.
[0308] In some instances, the antibody comprises the VH CDRs 1-3 and the VL CDRs 1-3 (e.g., according to Kabat) of KB001 and comprises a VH having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs: 29-32. In some instances, the antibody comprises the VH CDRs 1-3 and the VL CDRs 1-3 (e.g., according to Kabat) of KB001 and comprises a VL having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs:33-36. In some instances, the antibody comprises the VH CDRs 1-3 and the VL CDRs 1-3 (e.g., according to Kabat) of KB001 and comprises a VH having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%. at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO:29-32 and a VL having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of SEQ ID NO: 33-36.Attorney Docket No. 58285-0010WO1
[0309] In some instances, the antibody comprises the VH and VL of an antibody described in Table 2 (e.g.. the VH and VL of antibody H5, i.e.. SEQ ID NOs: 30 and 33, respectively). In some instances, the antibody comprises the HC and LC of an antibody described in Table 2 (e.g., the CH and LC of antibody H5-K222A, i.e., SEQ ID NOs:263 and 253, respectively).
[0310] In some instances, the antibody comprises the VH CDRs 1-3 of KB001 (see Table 1, e.g., SEQ ID NOs:3-5) and a heavy chain having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs:245, 261, 247, 263, 249, 265, 251, and 267. In some instances, the antibody comprises the VL CDRs of KB001 (see Table 1, e.g., SEQ ID NOs:6-8) and a light chain having at least 80%. at least 85%. at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs:253, 255, 257, and 259. In some instances, the antibody comprises the VH CDRs 1-3 of KB001 (see Table 1, e.g.. SEQ ID NOs:3-5) and a heavy chain having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs:245, 261, 247, 263, 249, 265, 251, and 267. and the antibody comprises the VL CDRs of KB001 (see Table 1, e.g., SEQ ID NOs:6-8) and a light chain having at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identity to the amino acid sequence of any one of SEQ ID NOs:253, 255, 257. and 259. In some instances, the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity’ to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an amino acid other than lysine at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172. In some instances, the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an alanine (instead of a lysine) at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172.
[0311] The gingipain-binding epitope of KB001 and its humanized variants (e.g., H5) is within the amino acid sequences YTYTVYRDGTKIK (SEQ ID NO:39) andAttorney Docket No. 58285-0010WO1
[0312] YCVEVKYTAGVSPK (SEQ ID NO:40) in RgpA from P. gingivalis. An exemplary amino acid sequence of RgpA from P. gingivalis W50 is presented in SEQ ID NO:41. This disclosure features antibodies that bind to P. gingivalis within the sequence YCVEVKYTAGVSPK (SEQ ID NO:40). This disclosure features antibodies that bind to the same epitope as H5 or KB001. Epitopes for H5 and KB001 are described in US Publication Nos. 2023 / 0365662 and 2024 / 0400654, and are incorporated by reference herein. This disclosure also features antibodies that competitively inhibit binding of H5 to human P. gingivalis or a protein thereof (e.g., RgpA (e.g., SEQ ID NO:41), Kgp (e.g., SEQ ID NO:42), or HagA (e g., SEQ ID NO:43)).
[0313] In some instances, the antibody comprises a heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an amino acid other than lysine at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172. In some instances, the antibody comprises a heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity’ to the sequence of SEQ ID NO: 172, wherein the Fc region compnses an alanine (instead of a lysine) at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172.
[0314] In some instances, a VH or HC of an antibody described herein comprises a signal peptide of SEQ ID NO:26. In some instances, a VL or LC of an antibody described herein comprises a signal peptide of SEQ ID NO: 27.
[0315] Table 1. KB001 Sequences
[0316]
[0317] Attorney Docket No. 58285-0010WO1
[0318]
[0319] Table 2. Humanized KB001 VH, VL, HC, and LC Sequences
[0320]
[0321] Attorney Docket No. 58285-0010WO1
[0322]
[0323] In some instances, the antibody is an immunoglobulin comprising a heavy chain and a light chain. In some instances, the antibody comprises an IgGl, an IgG2, or an IgG4 heavy chain constant region. In some instances, the antibody comprises a human IgGl heavy chain constant region. In some instances, the antibody comprises a human IgG2 heavy chain constant region. In some instances, the antibody comprises a human IgG4 heavy chain constant region. In some instances, the antibody comprises a kappa or a lambda light chain constant region. In some instances, the antibody comprises a human kappa light chain constant region. In some instances, the antibody comprises a human lambda light chain constant region.
[0324] In some instances, the antibody is an immunoglobulin comprising a human IgGl heavy chain constant region and a human Ig kappa light chain constant region.
[0325] In some instances, the antibody is an antibody fragment comprising at least one antigen-binding site. In some embodiments, the antibody or antibody fragment is a Fab, Fab',Attorney Docket No. 58285-0010WO1
[0326] F(ab')2, Fv, scFv, (scFv)2, single chain antibody, dual variable region antibody, single variable region antibody, linear antibody, diabody, nanobody, or a V region antibody.
[0327] In some instances, the antibody is a bispecific antibody. In some instances, the bispecific antibody comprises a first VH and a first VL of a first antibody described herein (e.g., H5) and a second VH and a second VL of a second antibody. Bispecific antibodies are antibodies that have binding specificities for at least two different epitopes. Exemplary bispecific antibodies may bind to two different epitopes of a gingipain protein. Other such antibodies may combine a P. gingivalis binding site with a binding site for another antigen. Bispecific antibodies can be prepared as full length antibodies or low molecular weight forms thereof (e.g., F(ab')2 bispecific antibodies, sc(Fv)2 bispecific antibodies, diabody bispecific antibodies).
[0328] ANTIBIOTICS
[0329] The ADCs described herein comprise an antibiotic payload. In some instances, the antibiotic is a gram-negative antibiotic. In some instances, the antibiotic is a gram-positive antibiotic.
[0330] In some instances, the antibiotic is a fluoroquinolone. Fluoroquinolones are a class of antibiotics widely used to treat upper and lower respiratory tract infections. Nonlimiting examples of fluoroquinolones include moxifloxacin, sitafloxacin, ciprofloxacin, levofloxacine, gemifloxacine, tosufloxacin, delafloxacin, and monofloxacin.
[0331] In some instances, the antibiotic is moxifloxacin. The structure of moxifloxacin is as follows:
[0332]
[0333] (moxifloxacin).
[0334] In some instances, the antibiotic is sitafloxacin. The structure of sitafloxacin is as follows:Attorney Docket No. 58285-0010WO1
[0335]
[0336] (sitafloxacin).
[0337] In some instances, the antibiotic is metronidazole. The structure of metronidazole is as follows:
[0338]
[0339] (metronidazole).
[0340] In some instances, the antibiotic is amoxicillin. The structure of amoxicillin is as follows:
[0341]
[0342] (amoxicillin).
[0343] In some instances, the antibiotic is one used to treat a gingival infection. Non-limiting examples of antibiotics used to treat a gingival infection include penicillin, amoxicillin, moxifloxacin, metronidazole, and clindamycin.
[0344] In some instances, the antibiotic is an antibiotic having a site amenable to attach a linker for conjugation, e.g., -NH or -OH groups. Non-limiting examples of NH-containing antibiotics include sitafloxacin, lolamycin, ETX0462. and azanidazole. An example of an OH-containing antibiotic is metronidazole.Attorney Docket No. 58285-0010WO1
[0345] LINKERS
[0346] Provided herein are linkers, e.g., for use in an ADC described herein. The linkers described herein comprise (i) a covalent protein binding moiety and (ii) a self-immolative linker comprising an arginine or lysine. The linkers described herein are attached to an antibiotic (e.g., sitafloxacin) described herein and are useful in an ADC as described herein. The linkers described herein are selectively cleaved by an arginine or lysine-specific protease (e.g., RgpA, RgpB, or Kgp).
[0347] Targeting cleavage selectivity, particularly relative to kallikreins, a general design for a linker sequence is:
[0348] Maleimide-(Small, Hydrophilic)-(Arg or Lys)-(Large, Hydrophobic)-(Drug-linking Group).
[0349] Most kallikreins tend to prefer small side chains at the PF position (following the arginine / lysine), usually a valine or serine. A large hydrophobic residue at the corresponding position in the ADC linker sequence serves to further minimize cleavage by most kallikreins.
[0350] An acceptable design for the peptide-drug linkage would result in the release of the drug moiety in a form identical to the original drug molecule on which the ADC is based, without modifications required by linkage to the peptide. In some instances, this is achieved using a self-immolating spacer, such as para-amino benzyloxycarbonyl (PABC), which is stable when incorporated into a peptide chain, but which undergoes elimination after the preceding peptide bond is cleaved.
[0351] COVALENT PROTEIN BINDING MOIETIES
[0352] o
[0353] In some embodiments, the covalent protein binding moiety is
[0354]
[0355] where “ ” is the point of attachment to Z of the self-immolative linker, where the spacer is an alkylene or a polyethylene glycol (PEG) chain as defined herein, and E is an electrophilic group that is reactive toward the SH of a cysteine residue on the antibody to form a covalent bond to the antibody.
[0356] In some embodiments, the spacer is -(CH2)n, where n is from 1 to 20, e g., 1-20, 2-18, 4-16. 6-14. 8-12. 1-2, 2-4, 4-6. 6-8, 8-10, 10-12. 12-14, 14-16, 16-18. or 18-20. In some embodiments, n is 3-7. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5.Attorney Docket No. 58285-0010WO1
[0357] In some embodiments, the spacer is 1-20 PEG monomer units (i.e.,
[0358]
[0359] , e.g., m is 1-20, 2-18, 4-16, 6-14, 8-12, 1-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-14, 14-16, 16-18, or 18-20. In some embodiments, m is 1-5. In some embodiments, m is 1-10. In some embodiments, m is 1-15. In some embodiments, m is 15-20. In some embodiments, m is 3-7. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5.
[0360] In some embodiments, the electrophilic group. E, is a maleimide or a maleamic ester, e.g., maleamic methyl ester. In some embodiments, the covalent protein binding moiety is OMe
[0361]
[0362] 0. In some embodiments, the covalent protein binding moiety is
[0363] P O
[0364] l| N— [r-spacer A f f5*
[0365] 0. It is understood by a person of ordinary skill in the relevant art that the forgoing electrophilic groups react with an -SH group through 1,4-conjugate addition, which creates a covalent bond to the side-chain functionality of a cysteine residue of a protein, e.g.:
[0366]
[0367] Accordingly, the reaction of the covalent protein binding moiety' as described herein with an antibody having -SH side chains results in an antibody drug conjugate.
[0368] In some embodiments, the covalent protein binding moiety is selected from the group
[0369] consisting
[0370]
[0371] ; wherein
[0372]
[0373] is the point of attachment to Z of the self-immolative linker;
[0374] indicates the point of attachment to a cysteine residue of the antibody; and
[0375] n and m is an integer from 1-20.Attorney Docket No. 58285-0010WO1
[0376] In some embodiments, the covalent protein binding moiety
[0377]
[0378] , wherein is the point of attachment to Z of the self-immolative linker,L‘*?’ indicates the point of attachment to a cysteine residue of the antibody (at the SH side chain), and n is 1-20. In some embodiments, n is 5.
[0379] In some embodiments, the covalent protein binding moiety is
[0380]
[0381] wherein “ ” is the point of attachment to Z of the selfimmolative linker, indicates the point of attachment to a cysteine residue of the antibody, and m is 1-20. In some embodiments, m is 5.
[0382] SELF-IMMOLATIVE LINKERS
[0383] In some embodiments, the self-immolative linker is:
[0384]
[0385] wherein
[0386] ‘ is the point of attachment to the antibiotic, optionally wherein “-’ isthe point of attachment to an -NH2. -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, and
[0387]
[0388] is the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;
[0389] LAis a bond
[0390]
[0391] LBis a bond
[0392]
[0393] indicates the point of attachment to
[0394]
[0395]
[0396] selected from phenylene, pyridylene, thiazolylene, and triazolylene;
[0397] Y is absent or a self-immolating spacer capable of elimination after proteolytic cleavage of K; R1and R2are independently selected from hydrogen and C1-C6 alkyl;
[0398] R3and R4are independently selected from hydrogen and C1-C6 alkyl;
[0399] R ' and R6are independently selected from hydrogen and C1-C6 alkyl;
[0400] K is Lysine or Arginine;Attorney Docket No. 58285-0010WO1
[0401] Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, leucine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; and
[0402] is the point of attachment to the covalent protein binding moiety.
[0403] In some embodiments, Y is a self-immolating spacer capable of elimination after proteolytic cleavage of K.
[0404] In some embodiments, the self-immolative linker is:
[0405]
[0406] is the point of attachment to the antibiotic, optionally wherein “JJ” is the point of attachment to an -NH2. -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, and
[0407]
[0408] is the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;
[0409] LAis a bond
[0410]
[0411] LBis a bond
[0412]
[0413] indicates the point of attachment to
[0414]
[0415]
[0416] selected from phenylene, pyridylene, thiazolylene, and triazolylene;
[0417] Y is absent, -NR3-CH2CH2-NR4-C(O)-, or -NR5-(CH2)o-pyridylene-NR6-C(O)- )-, wherein an R7is attached to the pyridylene;
[0418] R1and R2are independently selected from hydrogen and C1-C6 alkyl;
[0419] R3and R4are independently selected from hydrogen and C1-C6 alkyl;
[0420] R5and R6are independently selected from hydrogen and C1-C6 alkyl;
[0421] R7is hydrogen or -(C1-C6 alkylene)p-(O-CH2CH2)r-OR8;
[0422] R8is selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;
[0423] 0 is 0 or 1;
[0424] p is 0 or 1;
[0425] r is an integer from 1 to 20;
[0426] K is Lysine or Arginine;
[0427] Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; andAttorney Docket No. 58285-0010WO1
[0428] “*’■ is the point of attachment to the covalent protein binding moiety.
[0429] In some embodiments, the self-immolative linker is
[0430]
[0431] “ ' ” is the point of attachment to an NH group of an antibiotic;
[0432] LAis a bond
[0433]
[0434] LBis a bond
[0435]
[0436] indicates the point of attachment to
[0437]
[0438] R1and R2are independently selected from hydrogen and C1-C6 alkyl;
[0439] is a ring selected from phenylene, thiazolylene, and triazolylene;
[0440] K is Lysine;
[0441] Z is an amino acid; and
[0442] is the point of attachment to the covalent protein binding moiety.
[0443] In some embodiments, R1and R2are both hydrogen. In some embodiments, one of R1and R2is hydrogen and the other one of R1and R2is C1-C6 alkyl. In some embodiments, R1and R2are independently selected C1-C6 alkyl. In some embodiments, one of R1and R2is hydrogen and the other one of R1and R2is methyl. In some embodiments, R1and R2are methvl.
[0444] In some embodiments,
[0445]
[0446] is phenylene. In some embodiments,
[0447]
[0448]
[0449] In some embodiments,
[0450]
[0451] is pyridylene. In some embodiments,
[0452]
[0453] In some embodiments,
[0454]
[0455] . In some embodiments,
[0456]
[0457] . In someAttorney Docket No. 58285-0010WO1
[0458] embodiments,
[0459]
[0460] . In some embodiments,
[0461]
[0462] embodiments,
[0463]
[0464] In some embodiments.
[0465]
[0466] is thiazolylene. In some embodiments,
[0467]
[0468] R3
[0469] *
[0470]
[0471] , where R3is selected from hydrogen, C1-C3 haloalkyl. and halo.
[0472]
[0473] indicates the point of attachment to LB, and indicates the point of attachment to LA.
[0474] In some embodiments,
[0475]
[0476] where “ ' ” indicates the point of attachment to LB, and
[0477]
[0478] indicates the point of attachment to LA.
[0479] In some embodiments, LAis a bond.
[0480] In some embodiments,
[0481]
[0482] In some embodiments, LBis a bond.
[0483] In some embodiments, LAis a bond and LBis a bond.
[0484]
[0485] indicates the point of
[0486] attachment t
[0487]
[0488] In some embodiments, Y is absent.
[0489] In some embodiments, Y is -NR3-CH2CH2-NR4-C(O)-.
[0490] In some embodiments, Y is -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein an R7is attached to the pyridylene.
[0491] In some embodiments, the -pyridylene- wherein an R7is attached to the pyridylene is
[0492]
[0493] In some embodiments, the -pyridylene- attached to an R7is
[0494]
[0495] Attorney Docket No. 58285-0010WO1
[0496] some embodiments, the -pyridylene- attached to an R7is
[0497]
[0498] . In some embodiments,
[0499] the -pyridylene- attached t
[0500]
[0501] some embodiments, the -pyridylene-
[0502] attached to an R7is
[0503]
[0504] . In some embodiments, the -pyridylene- attached to an R7is
[0505] ~
[0506]
[0507] . In some embodiments, the -pyridylene- attached to an R is
[0508]
[0509]
[0510] ,
[0511]
[0512] In some embodiments, Y is -NR3-CH2CH2-NR4-C(O)- or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein an R7is attached to the pyridylene. In some embodiments, Y is -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein an R7is attached to the pyridylene.
[0513] In some embodiments, R7is hydrogen.
[0514] In some embodiments, R7is -(C1-C6 alkylene)p-(O-CH2CH2)r-OR8.
[0515] In some embodiments, LBis absent and Y is -NR3-CH2CH2-NR4-C(O)- or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein an R7is attached to the pyridylene.
[0516] In some embodiments, the R7C1-C6 alkylene is methylene. In some embodiments, the R7C1-C6 alkylene is ethylene.Attorney Docket No. 58285-0010WO1
[0517] In some embodiments, R8is hydrogen. In some embodiments, R8is and C1-C6 alkyl substituted with hydroxy. In some embodiments, R8is C1-C6 alkyl. In some embodiments, R8is methyl.
[0518] In some embodiments, o is 0. In some embodiments, o is 1.
[0519] In some embodiments, p is 0. In some embodiments, p is 1.
[0520] In some embodiments, r is an integer from 1 to 5. In some embodiments, r is an integer from 6 to 10. In some embodiments, r is an integer from 11 to 15. In some embodiments, r is an integer from 16 to 20. In some embodiments, r is 5.
[0521]
[0522] absent.
[0523] In some embodiments, K is arginine. In some embodiments, K is lysine.
[0524] In some embodiments, Z is valine. In some embodiments, Z is serine. In some embodiments, Z is asparagine. In some embodiments, Z is glycine. In some embodiments, Z is alanine. In some embodiments, Z is valine or serine.
[0525] In some embodiments, the self-immolative linker is
[0526]
[0527] In some embodiments, the self-immolative linker is
[0528]
[0529] In some embodiments, the self-immolative linker is
[0530]
[0531] In some embodiments, the self-immolative linker isAttorney Docket No. 58285-0010WO1
[0532]
[0533] In some embodiments, the self-immolative linker is
[0534]
[0535] In some embodiments, the self-immolative linker i
[0536]
[0537] In some embodiments, the self-immolative linker i
[0538]
[0539] In some embodiments, the self-immolative linker is
[0540]
[0541] In some embodiments, the self-immolative linker is
[0542]
[0543] In some embodiments, the self-immolative linker isAttorney Docket No. 58285-0010WO1
[0544]
[0545] In some embodiments, self-immolative linker is
[0546]
[0547] In some instances, the ammo acid preceding the lysine (P2 position) in the self-immolative linker balances a high rate of cleavage by RgpA, RgpB, or Kgp with minimal cleavage by other proteases in the oral cavity, with a priority on minimizing kallikrein activity. Serine, an amino acid with moderate properties, demonstrated lowered reaction rate with kallikrein when at the P2 position, and a polar character that could enhance linkerpayload solubility, was chosen to precede the targeted lysine in the self-immolative linker. Alternative choices at this position that might ensure minimal cleavage by kallikreins, and kallikrein in particular, include valine, asparagine, glycine, alanine, or other small, polar or acidic amino acids. Thus, in some instances, Z is serine, asparagine, glycine, alanine, or other small, polar or acidic amino acid. In some instances, Z is valine. In some instances, Z is serine.
[0548] LINKER-PAYLOADS
[0549] Also provided herein are linker-payloads, wherein the linker-payload comprises a covalent protein binding moiety described herein, a self-immolative linker comprising an arginine or lysine described herein, and a payload, wherein the payload is an antibiotic. In some instances,
[0550] (a) the self-immolative linker is
[0551]
[0552] , wherein
[0553] is the point of attachment to the antibiotic, optionally wherein
[0554]
[0555] i s the point of attachment to an -NH2, -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, and is the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;Attorney Docket No. 58285-0010WO1
[0556] LAis a bond
[0557]
[0558] o
[0559] I)
[0560] , jT (7) LBis a bond or, where “**” indicates the point of attachment to; (?) is selected from phenylene, thiazolylene, and triazolylene;
[0561] Y is absent, -NR3-CH2CH2-NR4-C(O)-, or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein R7is attached to the pyridylene;
[0562] R1and R2are independently selected from hydrogen and C1-C6 alkyl;
[0563] R3and R4are independently selected from hydrogen and C1-C6 alkyl;
[0564] R5and R6are independently selected from hydrogen and C1-C6 alkyl;
[0565] R7is hydrogen or -(C1-C6 alkylene)p-(O-CH2CH2)r-OR8;
[0566] R8is selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;
[0567] o is 0 or 1;
[0568] p is 0 or 1;
[0569] r is an integer from 1 to 20;
[0570] K is Lysine or Arginine;
[0571] Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, leucine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; and
[0572] is the point of attachment to the covalent protein binding moiety; and
[0573] (b) the covalent protein binding moiety is selected from the group consisting of
[0574]
[0575] wherein “-’ isthe point of attachment to Z of the self-immolative linker;
[0576] indicates the point of attachment to a cysteine residue of the antibody; and
[0577] n and m is an integer from 1-20.
[0578] In some instances,
[0579] (a) the self-immolative linker is
[0580]
[0581] Attorney Docket No. 58285-0010WO1
[0582] " S' ” is the point of attachment to the antibiotic, optionally wherein “ S' " is the point of attachment to an -NH2 of the antibiotic;
[0583] R1and R1are independently selected from hydrogen and C1-C6 alkyl;
[0584] Q is a ring selected from phenylene, thiazolylene, and triazolylene;
[0585] K is Lysine;
[0586] Z is a natural amino acid; and
[0587] is the point of attachment to the covalent protein binding moiety; and
[0588] (b) the covalent protein binding moiety is selected from the group consisting of
[0589]
[0590] is the point of attachment to Z of the self-immolative linker;
[0591] “*’■ indicates the point of attachment to a cysteine residue of the antibody; and
[0592] n and m is an integer from 1-20.
[0593] ANTIBODY-DRUG CONJUGATE
[0594] Provided herein are antibody-drug conjugates comprising a linker described herein and an antibiotic.
[0595] In some instances, the ADC comprises a linker-payload described herein, wherein the linker-payload comprises a covalent protein binding moiety, a self-immolative linker comprising (i) an arginine or lysine, and (ii) a payload, wherein the payload is an antibiotic; wherein
[0596] (a) the self-immolative linker is
[0597]
[0598] “ S' ” is the point of attachment to the antibiotic, optionally wherein
[0599]
[0600] i s the point of attachment to an -NH2, -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, and “ S' ” is the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;
[0601] LAis a bond
[0602]
[0603] Attorney Docket No. 58285-0010WO1
[0604] T) LBis a bond
[0605]
[0606] indicates the point of attachment to; 0 is selected from phenylene, thiazolylene, and triazolylene;
[0607] Y is absent, -NR3-CH2CH2-NR4-C(O)-, or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein R7is attached to the pyridylene;
[0608] R1and R2are independently selected from hydrogen and C1-C6 alkyl;
[0609] R3and R4are independently selected from hydrogen and C1-C6 alkyl:
[0610] R5and R6are independently selected from hydrogen and C1-C6 alkyl;
[0611] R7is hydrogen or -(C1-C6 alkylene)p-(O-CH2CH2)r-OR8;
[0612] R8is selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;
[0613] o is 0 or 1;
[0614] p is 0 or 1;
[0615] r is an integer from 1 to 20;
[0616] K is Lysine or Arginine;
[0617] Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; and
[0618] is the point of attachment to the covalent protein binding moiety; and
[0619] (b) the covalent protein binding moiety is selected from the group consisting of
[0620]
[0621] ” is the point of attachment to Z of the self-immolative linker;
[0622] indicates the point of attachment to a cysteine residue of the antibody; and
[0623] n and m is an integer from 1-20.
[0624] In some instances, the ADC comprises a linker-payload described herein, wherein the linker-payload comprises a covalent protein binding moiety, a self-immolative linker comprising (i) an arginine or lysine, and (ii) a payload, wherein the payload is an antibiotic; wherein
[0625] (a) the self-immolative linker is
[0626]
[0627] Attorney Docket No. 58285-0010WO1
[0628] is the point of attachment to the antibiotic, optionally wherein
[0629]
[0630] is the point of attachment to an -NH2 of the antibiotic;
[0631] R1and R1are independently selected from hydrogen and C1-C6 alkyl;
[0632] Q is a ring selected from phenylene, thiazolylene, and triazolylene;
[0633] K is Lysine;
[0634] Z is a natural amino acid (e.g., serine, asparagine, glycine, alanine, or other small, polar or acidic amino acids), optionally wherein Z is serine; and
[0635] is the point of attachment to the covalent protein binding moiety; and
[0636] (b) the covalent protein binding moiety is selected from the group consisting of
[0637]
[0638] ” is the point of attachment to Z of the self-immolative linker;
[0639] indicates the point of attachment to a cysteine residue of the antibody; and
[0640] n and m is an integer from 1-20. In some instances, the antibody drug conjugate comprises an antibody described herein.
[0641] In some instances, the antibody drug conjugate comprises an antibody described herein, a linker described herein, and an antibiotic described herein.
[0642] In some instances, the antibody drug conjugate has a general structure of:
[0643]
[0644] (Formula I), wherein Q is 1 to 14, wherein the drug is an antibiotic (e.g., moxifloxacin, metronidazole, amoxicillin, or sitafloxacin). In some instances. Q is 1 to 8. In some instances, Q is 3 to 5. In some instances, Q is 1.
[0645] In some instances, the antibody drug conjugate has a general structure of:Attorney Docket No. 58285-0010WO1
[0646]
[0647] (Formula XIV), wherein Q is 1 to 14. wherein the drug is an antibiotic (e.g.. moxifloxacin, metronidazole, amoxicillin, or sitafloxacin). In some instances, Q is 1 to 8. In some instances, Q is 3 to 5. In some instances, Q is 1.
[0648] In some instances, the antibody drug conjugate has a general structure of:
[0649]
[0650] (Formula XV), wherein Q is 1 to 14, wherein the drug is an antibiotic (e.g., moxifloxacin, metronidazole, amoxicillin, or sitafloxacin). In some instances, Q is 1 to 8. In some instances, Q is 3 to 5. In some instances, Q is 1.
[0651] In some instances, the antibody drug conjugate has a general structure of:
[0652]
[0653] (Formula II)
[0654] wherein Q is 1 to 14, wherein the drug is an antibiotic (e.g., moxifloxacin, metronidazole, amoxicillin, or sitafloxacin). In some instances, Q is 1 to 8. In some instances, Q is 3 to 5. In some instances, Q is 1.Attorney Docket No. 58285-0010WO1
[0655] In some instances, the antibody drug conjugate has a general structure of:
[0656]
[0657] (Formula XVI)
[0658] wherein Q is 1 to 14. wherein the drug is an antibiotic (e.g., moxifloxacin, metronidazole, amoxicillin, or sitafloxacin). In some instances, Q is 1 to 8. In some instances, Q is 3 to 5. In some instances, Q is 1.
[0659] In some instances, the antibody drug conjugate has a general structure of:
[0660]
[0661] (Formula XVII)
[0662] wherein Q is 1 to 14, wherein the drug is an antibiotic (e.g., moxifloxacin, metronidazole, amoxicillin, or sitafloxacin). In some instances. Q is 1 to 8. In some instances, Q is 3 to 5. In some instances, Q is 1.
[0663] wherein Q is 1 to 14, wherein the drug is an antibiotic (e.g., moxifloxacin, metronidazole, amoxicillin, or sitafloxacin). In some instances, Q is 1 to 8. In some instances, Q is 3 to 5. In some instances. Q is 1.
[0664] The above two structures are drawn to convey that the antibody has 1 to 14 (e.g., 1 to 8) linker-antibiotic moieties covalently attached to the antibody, wherein each linkerantibiotic moiety is show n within the square brackets and Q indicates the number of moieties in the square brackets attached to the antibody. The S within the square brackets is part of a cysteine residue on the antibody. Thus, where Q is. e.g., 4, the ADC comprises four linker-Attorney Docket No. 58285-0010WO1
[0665] antibiotic moi eties conjugated independently to four cysteines on the antibody of the ADC (i.e., a drug antibody ratio (DAR) value of 4).
[0666] In some instances, the ADC comprises an antibody having one linker-antibiotic moiety attached to the antibody, e.g., the ADC has a general structure of:
[0667]
[0668] (Formula IV).
[0669] In some instances, the ADC comprises an antibody having two linker-antibiotic moieties attached to the antibody, e.g., the ADC has a general structure of:
[0670]
[0671] Attorney Docket No. 58285-0010WO1
[0672]
[0673] (Formula VI).
[0674] In some instances, the ADC comprises an antibody having three linker-antibiotic moieties attached to the antibody, e g., the ADC has a general structure of:
[0675]
[0676] VII) or
[0677] (Formul
[0678]
[0679] In some instances, the ADC comprises an antibody having four linker-antibiotic moieties attached to the antibody, e.g.. the ADC has a general structure of:Attorney Docket No. 58285-0010WO1
[0680]
[0681] IX) or
[0682] (Formul
[0683]
[0684] Additional ADC conjugates would be rendered accordingly, indicating the subscript ”2" orL‘3”, or ”4" with values corresponding to the number of moieties contained within the brackets attached to the antibody. These ADC structures correspond to species having DAR values with the indicated number Q.
[0685] In some instances, Q is an integer, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and such. In some instances, Q is a non-integer value e.g., a decimal between 1 and 14, e.g., a decimal between 1 and 2, such as 1.0, 1.2. 1.3, 1.4, 1.5, 1.6. 1.7, 1.8, 1.9, or 2.0; between 2 and 3, such as 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3.0; between 3 and 4, such as 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0; between 4 and 5 such as 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0, between 5 and 6 such as 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0, between 6 and 7 such as 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9. or 7.0, between 7 and 8 such as 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0. In some instances, Q is 1.
[0686] In some instances, Q is a number with a value greater than 0 and less than 10, e.g., between 1 to 10, between 2 and 9, between 3 and 8, between 4 and 7, between 5 and 6; or between 1 and 2. between 2 and 3. between 3 and 4. between 4 and 5, between 5 and 6,Attorney Docket No. 58285-0010WO1
[0687] between 6 and 7. between 7 and 8, between 8 and 9, between 9 and 10, between 10 and 11, between 11 and 12, between 12 and 13, or between 13 and 14.
[0688] In some instances, Q is determined after conjugation and before any further modification of the ADC. In some instances, Q is determined after modification, e.g., deglycosylation of the ADC.
[0689] In some instances, the ADC comprises the structure of Formula I, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0690] In some instances, the ADC comprises the structure of Formula I, w herein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0691] In some instances, the ADC comprises the structure of Formula I, wherein the antibody compnses a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0692] In some instances, the ADC comprises the structure of Formula I, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0693] In some instances, the ADC comprises the structure of Formula I, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0694] In some instances, the ADC comprises the structure of Formula II, wherein the antibody compnses a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0695] In some instances, the ADC comprises the structure of Formula II, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.Attorney Docket No. 58285-0010WO1
[0696] In some instances, the ADC comprises the structure of Formula II, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0697] In some instances, the ADC comprises the structure of Formula II, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0698] In some instances, the ADC comprises the structure of Formula II, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0699] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0700] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0701] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0702] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0703] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0704] In some instances, the ADC comprises the structure of Formula XV, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0705] In some instances, the ADC comprises the structure of Formula XV, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VLAttorney Docket No. 58285-0010WO1
[0706] CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8. respectively.
[0707] In some instances, the ADC comprises the structure of Formula XII, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0708] In some instances, the ADC comprises the structure of Formula XV, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0709] In some instances, the ADC comprises the structure of Formula XV, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0710] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO: 9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0711] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8. respectively.
[0712] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0713] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody compnses a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0714] In some instances, the ADC comprises the structure of Formula XVI, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0715] In some instances, the ADC comprises the structure of Formula XVII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.Attorney Docket No. 58285-0010WO1
[0716] In some instances, the ADC comprises the structure of Formula XVII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0717] In some instances, the ADC comprises the structure of Formula XVII, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0718] In some instances, the ADC comprises the structure of Formula XVII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0719] In some instances, the ADC comprises the structure of Formula XVII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0720] In some instances, the antibiotic treats a gram-negative bacterial infection. In some instances, the antibiotic treats a gram-positive bacterial infection. In some instances, the antibiotic is a fluoroquinolone.
[0721] In some instances, the antibiotic is moxifloxacin.
[0722] In some instances, the antibiotic is metronidazole (MTZ).
[0723] In some instances, the antibiotic is sitafloxacin.
[0724] In some instances, the antibiotic is amoxicillin.
[0725] In some instances, the antibiotic is sitafloxacin and the ADC comprises:
[0726]
[0727] (Formula XI), wherein Q is 1-14; or
[0728] orAttorney Docket No. 58285-0010WO1
[0729]
[0730] (Formula XII), wherein Q is 1-14. In some instances, Q is 1 to 8. In some instances Q is 3-5.
[0731] In some instances, the antibiotic is sitafloxacin and the ADC comprises:
[0732]
[0733] (Formula XIII),
[0734] wherein Q is 1 to 14. In some instances. Q is 1 to 8. In some instances, Q is 3 to 5.
[0735] In some instances, the antibiotic is metronidazole and the ADC comprises:
[0736]
[0737] (Formula XVIII).
[0738] wherein Q is 1 to 14. In some instances. Q is 1 to 8. In some instances, Q is 3 to 5.
[0739] In some instances, the antibiotic is metronidazole and the ADC comprises:Attorney Docket No. 58285-0010WO1
[0740]
[0741] (Formula XIX),
[0742] wherein Q is 1 to 14. In some instances, Q is 1 to 8. In some instances, Q is 3 to 5.
[0743] In some instances, the antibiotic is metronidazole and the ADC comprises:
[0744]
[0745] (Formula XlX-i),
[0746] wherein Q is 1 to 14. In some instances, Q is 1 to 8. In some instances, Q is 3 to 5.
[0747] In some instances, the antibiotic is metronidazole and the ADC comprises:
[0748]
[0749] (Formula XX),
[0750] wherein Q is 1 to 14. In some instances, Q is 1 to 8. In some instances, Q is 3 to 5.
[0751] In some instances, the antibiotic is amoxicillin and the ADC comprises:Attorney Docket No. 58285-0010WO1
[0752]
[0753] (Formula XXI),
[0754] wherein Q is 1 to 14. In some instances, Q is 1 to 8. In some instances, Q is 3 to 5.
[0755] In some instances, the antibiotic is sitafloxacin and the ADC comprises:
[0756]
[0757] (Formula XXII),
[0758] wherein Q is 1 to 14. In some instances, Q is 1 to 8. In some instances, Q is 3 to 5.
[0759] In some instances, the antibiotic is moxifloxacin and the ADC comprises:
[0760]
[0761] (Formula XXIII).
[0762] wherein Q is 1 to 14. In some instances, Q is 1 to 8. In some instances, Q is 3 to 5.Attorney Docket No. 58285-0010WO1
[0763] In some instances, the ADC comprises the structure of Formula XI, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0764] In some instances, the ADC comprises the structure of Formula XI, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, aVL CDR2, and aVL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0765] In some instances, the ADC comprises the structure of Formula XL wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0766] In some instances, the ADC comprises the structure of Formula XI, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0767] In some instances, the ADC comprises the structure of Formula XI, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0768] In some instances, the ADC comprises the structure of Formula XIII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0769] In some instances, the ADC comprises the structure of Formula XIII, wherein the antibody compnses a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, aVL CDR2, and aVL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0770] In some instances, the ADC comprises the structure of Formula XIII, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0771] In some instances, the ADC comprises the structure of Formula XIII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.Attorney Docket No. 58285-0010WO1
[0772] In some instances, the ADC comprises the structure of Formula XIII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0773] In some instances, the ADC comprises the structure of Formula XVIII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0774] In some instances, the ADC comprises the structure of Formula XVIII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0775] In some instances, the ADC comprises the structure of Formula XVIII, wherein the antibody comprises a VH comprising the sequence of SEQ ID NOVO and a VL comprising the sequence of SEQ ID NO:33.
[0776] In some instances, the ADC comprises the structure of Formula XVIII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0777] In some instances, the ADC comprises the structure of Formula XVIII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0778] In some instances, the ADC comprises the structure of Formula XVIV, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0779] In some instances, the ADC comprises the structure of Formula XVIV, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDRL a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0780] In some instances, the ADC comprises the structure of Formula XVIV, wherein the antibody comprises a VH comprising the sequence of SEQ ID NOVO and a VL comprising the sequence of SEQ ID NO:33.Attorney Docket No. 58285-0010WO1
[0781] In some instances, the ADC comprises the structure of Formula XVIV, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0782] In some instances, the ADC comprises the structure of Formula XVIV, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0783] In some instances, the ADC comprises the structure of Formula XX, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0784] In some instances, the ADC comprises the structure of Formula XX, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0785] In some instances, the ADC comprises the structure of Formula XX, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0786] In some instances, the ADC comprises the structure of Formula XX, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0787] In some instances, the ADC comprises the structure of Formula XX, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0788] In some instances, the ADC comprises the structure of Formula XXL wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0789] In some instances, the ADC comprises the structure of Formula XXI, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8. respectively.Attorney Docket No. 58285-0010WO1
[0790] In some instances, the ADC comprises the structure of Formula XXI, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0791] In some instances, the ADC comprises the structure of Formula XXI, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0792] In some instances, the ADC comprises the structure of Formula XXI. wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0793] In some instances, the ADC comprises the structure of Formula XXII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0794] In some instances, the ADC comprises the structure of Formula XXII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8, respectively.
[0795] In some instances, the ADC comprises the structure of Formula XXII, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0796] In some instances, the ADC comprises the structure of Formula XXII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0797] In some instances, the ADC comprises the structure of Formula XXII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0798] In some instances, the ADC comprises the structure of Formula XXIII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37, and a VL comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO:9 or 37.
[0799] In some instances, the ADC comprises the structure of Formula XXIII, wherein the antibody comprises a VH comprising a VH CDR1, a VH CDR2, and a VH CDR3 comprising the amino acid sequences of SEQ ID NOs:3-5, respectively, and a VL comprising a VLAttorney Docket No. 58285-0010WO1
[0800] CDR1, a VL CDR2, and a VL CDR3 comprising the amino acid sequences of SEQ ID NOs:6-8. respectively.
[0801] In some instances, the ADC comprises the structure of Formula XXIII, wherein the antibody comprises a VH comprising the sequence of SEQ ID NO:30 and a VL comprising the sequence of SEQ ID NO:33.
[0802] In some instances, the ADC comprises the structure of Formula XXIII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0803] In some instances, the ADC comprises the structure of Formula XXIII, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:247 and a light chain comprising the sequence of SEQ ID NO:253.
[0804] PHARMACEUTICAL COMPOSITIONS AND KITS
[0805] The ADCs described herein can be formulated for use as or in pharmaceutical compositions. The pharmaceutical compositions may be used in the methods described herein, such as the methods of treatment and methods of delivering an antibiotic.
[0806] An ADC described herein can be formulated as a pharmaceutical composition for administration to a subject, e.g., to treat a disease or disorder described herein. Typically, a pharmaceutical composition includes a pharmaceutically acceptable carrier. As used herein, ■■pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The composition can include a pharmaceutically acceptable salt, e.g., an acid addition salt or a base addition salt (see, e.g., Berge, S. M., et al. (1977) J. Pharm. Sci. 66:1-19).
[0807] Pharmaceutical formulation is a well-established art, and is further described, e.g., in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20thed., Lippincott, Williams & Wilkins (2000) (ISBN: 0683306472); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Ed., Lippincott Williams & Wilkins Publishers (1999) (ISBN: 0683305727); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3rd ed. (2000) (ISBN: 091733096X).
[0808] Pharmaceutical compositions described herein can be formulated or adapted for administration to a subject via any route, e.g., any route approved by the Food and Drug Administration (FDA). Exemplary methods are described in the FDA’s CDER DataAttorney Docket No. 58285-0010WO1
[0809] Standards Manual, version number 004 (which is available at fda.gov / cder / dsm / DRG / drg00301.htm). For example, pharmaceutical compositions can be formulated or adapted for administration by inhalation (e.g., oral and / or nasal inhalation (e.g., via nebulizer or spray)), injection (e.g., intravenously, intra-arterial, subdermally, intraperitoneally, intramuscularly, and / or subcutaneously); and / or for oral administration, transmucosal administration, and / or topical administration (including topical (e.g., nasal) sprays, eye drops, and / or solutions).
[0810] The pharmaceutical compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form can depend on the intended mode of administration and therapeutic application. Typically, compositions for the agents described herein are in the form of injectable or infusible solutions.
[0811] In some instances, pharmaceutical compositions include an effective amount of an ADC described herein. The terms “effective amount” and “effective to treat,” as used herein, refer to an amount or a concentration of the described agent (e.g., ADC) or a pharmaceutical composition described herein utilized for a period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration for causing an intended effect or physiological outcome (e.g., treatment of / ’. gingivalis infection, treatment of a condition, disorder, or disease associated with aP. gingivalis infection, or symptoms thereof, treatment of peri-implantitis, periodontal disease, or bone loss associated with periodontal disease in a subject in need thereof).
[0812] Pharmaceutical compositions of this disclosure can include an ADC described herein and any pharmaceutically acceptable carrier and / or vehicle. In some instances, pharmaceutical compositions can further include one or more additional therapeutic agents in amounts effective for achieving a modulation of disease (e.g., P. gingivalis infection or a condition, disorder, or disease associated with aP. gingivalis infection; peri-implantitis, periodontal disease, or bone loss associated with periodontal disease) or disease symptoms.
[0813] Pharmaceutically acceptable carriers and adjuvants include carriers and adjuvants that may be administered to a subject together with a compound of this disclosure (e g., an ADC), and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
[0814] The pharmaceutical compositions disclosed herein can include one or more pharmaceutically acceptable salts. In some instances, the pharmaceutically acceptable saltsAttorney Docket No. 58285-0010WO1
[0815] include salts comprising hydrochloride, sodium, sulfate, acetate, phosphate or diphosphate, chloride, potassium, maleate, calcium, citrate, mesylate, nitrate, tartrate, aluminum, gluconate, and any combination thereof.
[0816] The pharmaceutical compositions of this disclosure may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
[0817] In some instances, the pharmaceutical composition comprises an ADC described herein and a pharmaceutically acceptable carrier.
[0818] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula I, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula I, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO:33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula I, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO 253.
[0819] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula II, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula II. and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL compnsing the sequence of SEQ ID NO:33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula II, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0820] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively, and wherein the antibiotic comprises sitafloxacin. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the antibody comprises a VH comprising the sequence of SEQ IDAttorney Docket No. 58285-0010WO1
[0821] NO:30 and a VL comprising the sequence of SEQ ID NO:33, and wherein the antibiotic comprises sitafloxacin. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253, and wherein the antibiotic comprises sitafloxacin.
[0822] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XI, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XI, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO:33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XI, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO 253.
[0823] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIII, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIII, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIII, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0824] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIV, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIV, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIV, and wherein the antibody comprises aAttorney Docket No. 58285-0010WO1
[0825] heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0826] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XV, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XV. and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XV, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO: 253.
[0827] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVI, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVI, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVI, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0828] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVII, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVII, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVII, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0829] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVIII, and wherein the antibody comprises VHAttorney Docket No. 58285-0010WO1
[0830] CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVIII, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XVIII, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO: 253.
[0831] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIX, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIX, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XIX, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0832] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XX. and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XX, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition compnses an ADC described herein, wherein the ADC comprises Formula XX, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0833] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXL and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXI, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL compnsing the sequence of SEQ IDAttorney Docket No. 58285-0010WO1
[0834] NO:33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXI, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO: 253.
[0835] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXII, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXII, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO: 33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXII, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0836] In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXIII, and wherein the antibody comprises VH CDRs 1-3 and VL CDRs 1-3 comprising the sequences of SEQ ID NOs:3-8, respectively. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXIII, and wherein the antibody comprises a VH comprising the sequence of SEQ ID NO: 30 and a VL comprising the sequence of SEQ ID NO:33. In certain instances, the pharmaceutical composition comprises an ADC described herein, wherein the ADC comprises Formula XXIII, and wherein the antibody comprises a heavy chain comprising the sequence of SEQ ID NO:263 and a light chain comprising the sequence of SEQ ID NO:253.
[0837] Also provided herein is a pharmaceutical composition comprising: (a) a means for treating aP. gingivalis infection in subject (e.g., human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the subject is a human.
[0838] Also provided herein is a pharmaceutical composition comprising: (a) a means for treating a condition, disorder, or disease associated with aP. gingivalis infection, or symptoms thereof in subject (e.g., human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the condition, disorder, or disease associated with aP. gingivalis infection is peri-implantitis, periodontal disease, or bone loss associated with periodontal disease. In some instances, the subject is a human.Attorney Docket No. 58285-0010WO1
[0839] Also provided herein is a pharmaceutical composition comprising: (a) a means for treating peri-implantitis, periodontal disease, or bone loss associated with periodontal disease in subject (e.g., human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the subject has aP. gingivalis infection. In some instances, the subject is a human.
[0840] Also provided herein is a pharmaceutical composition comprising: (a) a means for treating a longevity- or age-related disorder in subject (e.g.. human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the subject has a P. gingivalis infection. In some instances, the subject is a human.
[0841] Also provided herein is a pharmaceutical composition comprising: (a) a means for treating is an age-related cognitive disorder in subject (e.g., human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the subject has aP. gingivalis infection. In some instances, the subject is a human. In some instances, the age-related cognitive disorder is a dementia. In some instances, the age-related cognitive disorder is Alzheimer's disease. In some instances, the method further comprises determining that the subject has aP. gingivalis infection.
[0842] Also provided herein is a pharmaceutical composition comprising: (a) a means for treating periodontitis or an associated-systemic inflammatory disease in subject (e.g., human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the subject has aP. gingivalis infection. In some instances, the subject is a human. In some instances, the associated-systemic inflammatory disease is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease.
[0843] Also provided herein is a pharmaceutical composition comprising: (a) a means for treating a systemic inflammatory disease associated with aP. gingivalis infection in subject (e.g., human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the subject has aP. gingivalis infection. In some instances, the subject is a human. In some instances, the systemic inflammatory disease associated with aP. gingivalis infection is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease.
[0844] Also provided herein is a pharmaceutical composition comprising: (a) a means for delivering an antibiotic to a subject (e.g., human) in need thereof, and (b) a pharmaceutically acceptable carrier. In some instances, the subject is a human.
[0845] Also provided herein is a kit comprising an ADC described herein or a pharmaceutical composition described herein. In some instances, the kit is for use in aAttorney Docket No. 58285-0010WO1
[0846] method described herein. In some instances, the kit provides instructions for using the ADC or pharmaceutical composition in a method described herein.
[0847] METHODS OF PRODUCING ADCS
[0848] Also provided herein are methods of making an ADC described herein.
[0849] In some instances, the method of making an ADC described herein comprises: (a) providing an antibody described herein, (b) reducing the antibody, and (c) conjugating the reduced antibody to a linker described herein. In some instances, the method further comprises formulating the ADC as a sterile pharmaceutical composition.
[0850] In some instances, the method of making an ADC described herein comprises: (a) culturing a cell producing the antibody (e.g., a cell, e.g., a host cell, comprising one or more nucleic acids or one or more vectors encoding the antibody), (b) isolating the antibody, (c) reducing the isolated antibody, and (c) conjugating the reduced, isolated antibody to a linkerantibiotic moiety comprising a covalent protein binding moiety, a self-immolative linker comprising an arginine or lysine, and an antibiotic. In some instances, the method further comprises formulating the ADC as a sterile pharmaceutical composition.
[0851] Methods of producing antibodies are known in the art (see, e.g., US Publication Nos.
[0852] 2023 / 0365662 and 2024 / 0400654). Antibodies described herein may be produced in bacterial or eukaryotic cells. Some antibodies, e.g., Fabs and immunoglobulins, can be produced in bacterial cells, e.g., E. coli cells. Antibodies can also be produced in eukaryotic cells such as transformed cell lines (e g., CHO, 293E, COS). In addition, antibodies (e.g., scFvs) can be expressed in a yeast cell such as Pichia (see, e.g., Powers et al., J Immunol Methods. 251:123-35 (2001)), Hansenula, or Saccharomyces. To produce the antibody of interest, one or more polynucleotides encoding the antibody are constructed, introduced into one or more expression vectors, and then expressed in suitable host cells (e.g., CHO).
[0853] Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody.
[0854] In an exemplary system for antibody expression, a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain of an antibody described herein is introduced into dhfr-CHO cells by calcium phosphate-mediated transfection. Within the recombinant expression vector, the antibody heavy and light chain genes are each operatively linked to enhancer / promoter regulatory elements (e.g., derived from SV40. CMV,Attorney Docket No. 58285-0010WO1
[0855] adenovirus and the like, such as a CMV enhancer / AdMLP promoter regulatory element or an SV40 enhancer / AdMLP promoter regulatory element) to drive high levels of transcription of the genes. The recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection / amplification. The selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and the antibody is recovered from the culture medium.
[0856] Antibodies can also be produced by a transgenic animal. For example, U. S. Pat. No.
[0857] 5,849,992 describes a method of expressing an antibody in the mammary gland of a transgenic mammal. A transgene is constructed that includes a milk-specific promoter and nucleic acids encoding the antibody of interest and a signal sequence for secretion. The milk produced by females of such transgenic mammals includes, secreted-therein, the antibody of interest. The antibody can be purified from the milk, or for some applications, used directly. Animals are also provided comprising one or more of the nucleic acids described herein.
[0858] The antibodies of the present disclosure can be isolated from inside or outside (such as from the medium) of the host cell and purified as substantially pure and homogenous antibodies. Methods for isolation and purification commonly used for antibody purification may be used for the isolation and purification of antibodies, and are not limited to any particular method. Antibodies may be isolated and purified by appropriately selecting and combining, for example, column chromatography, filtration, ultrafiltration, salting out. solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, and recrystallization.
[0859] Chromatography includes, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). Chromatography can be carried out using liquid phase chromatography such as HPLC and FPLC. Columns used for affinity chromatography include protein A column and protein G column. Examples of columns using protein A column include Hyper D. POROS, and Sepharose FF (GE Healthcare Biosciences). The present disclosure also includes antibodies that are highly purified using these purification methods.
[0860] The antibodies described herein can be produced by any suitable method known in the art. Such methods range from direct protein synthesis methods to constructing a DNA sequence encoding polypeptide sequences and expressing those sequences in a suitable host.Attorney Docket No. 58285-0010WO1
[0861] See, e.g., International Patent Application Publication No. WO 2017 / 172260, which is incorporated by reference herein in its entirety, for a description of various methods for producing antibodies.
[0862] Methods for recombinant production of an antibody are known in the art, see, e.g., Co, M. S. et al., J. Immunol., 152:2968-2976 (1994); Better, M. and Horwitz, A. H., Methods in Enzymology, 178:476-496 (1989); Plueckthun, A. and Skerra, A., Methods in Enzymology, 178:476-496 (1989); Lamoyi, E., Methods in Enzymology. 121:652-663 (1989); Rousseaux, J. et al., Methods in Enzymology, (1989) 121:663-669 (1989); and Bird, R. E. et al., TIBTECH, 9:132-137 (1991); Carter et al., Bio / Technology, 10:163-167 (1992); U. S. Pat. No. 5,869,046.
[0863] Methods of producing ADCs comprising an antibody described herein, a linker described herein, and an antibiotic described herein are known in the art and described in the examples herein. See, e.g.. Example 1, below; which describes an exemplary method for generating a linker-antibiotic moiety for use in an ADC described herein. See, e.g., Example 2, below, which describes an exemplary method for conjugating a linker-antibiotic moiety to an antibody to produce an ADC.
[0864] METHODS OF USE
[0865] The ADCs described herein are useful in delivering an antibiotic to a subject in need thereof. The ADCs described herein are able to deliver an antibiotic (e.g., moxifloxacin, amoxicillin, metronidazole, or sitafloxacin) payload to, e.g., the teeth or the oral cavity of a subject (e.g., human) in need thereof. The antibiotic is selectively cleaved by an arginine or lysine-specific gingipain, releasing the antibiotic. Thus, also provided are methods of using the ADCs described herein.
[0866] Provided herein is a method of treating a / < gingivalis infection in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein.
[0867] Also provided herein is a method of treating a condition, disorder, or disease associated with aP. gingivalis infection, or symptoms thereof, in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein. In some instances, the condition, disorder, or disease associated with aP. gingivalis infection is peri-implantitis. In some instances, the condition, disorder, or disease associated with aP. gingivalis infection is periodontal disease. In someAttorney Docket No. 58285-0010WO1
[0868] instances, the condition, disorder, or disease associated with aP. gingivalis infection is bone loss associated with periodontal disease. In some instances, the subject has aP. gingivalis infection. In some instances, the method further comprises determining that the subject has a P. gingivalis infection.
[0869] Also provided herein is a method of treating peri-implantitis in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein, wherein the subject has aP. gingivalis infection. Methods of determining that the subject has a P. gingivalis infection are known in the art. In some instances, the method further comprises determining that the subject has a P. gingivalis infection.
[0870] Also provided herein is a method of treating periodontal disease in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein, wherein the subject has aP. gingivalis infection. In some instances, the method further comprises determining that the subject has a P. gingivalis infection.
[0871] Also provided herein is a method of treating bone loss associated with periodontal disease in a subject (e g., human) in need thereof, the method comprising administering to the subj ect a therapeutically effective amount of an ADC described herein, wherein the subj ect has aP. gingivalis infection. In some instances, the method further comprises determining that the subject has aP. gingivalis infection.
[0872] Also provided herein is a method of treating is a longevity- or age-related disorder in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein, wherein the subject has aP. gingivalis infection. In some instances, the method further comprises determining that the subject has P. gingivalis infection.
[0873] Also provided herein is a method of treating an age-related cognitive disorder in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein, w herein the subject has a P. gingivalis infection. In some instances, the age-related cognitive disorder is a dementia. In some instances, the age-related cognitive disorder is Alzheimer’s disease. In some instances, the method further comprises determining that the subject has P. gingivalis infection. Also provided herein is a method of treating periodontitis or an associated-systemic inflammatory’ disease in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein.Attorney Docket No. 58285-0010WO1
[0874] In some instances, the subject has aP. gingivalis infection. In some instances, the associated-systemic inflammatory disease is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease. In some instances, the method further comprises determining that the subject has aP. gingivalis infection.
[0875] Also provided herein is a method of treating a systemic inflammatory' disease associated with aP. gingivalis infection in a subject (e.g., human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of an ADC described herein. In some instances, the subject has aP. gingivalis infection. In some instances, the systemic inflammatory' disease associated with aP. gingivalis infection is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease. In some instances, the method further comprises determining that the subject has aP. gingivalis infection.
[0876] Also provided herein is a method of delivering an antibiotic (e.g., moxifloxacin, amoxicillin, metronidazole, or sitafloxacin) to a subj ect in need thereof, the method comprising administering to the subject an ADC described herein.
[0877] In some instances of the methods of use described herein, the subject is a human. In some instances of the methods of use described herein, the subject is a mammal, e.g., dog, cat, horse.
[0878] In some instances of the methods described herein, the ADC is delivered to the subject in the form of a pharmaceutical composition described herein.
[0879] In some instances, the ADC or pharmaceutical composition is administered to the subject via any route, e.g., any route approved by the Food and Drug Administration (FDA). Exemplary methods are described in the FDA’s CDER Data Standards Manual, version number 004 (which is available at fda.gov / cder / dsm / DRG / drg00301.htm). For example, the ADC or pharmaceutical composition may be administered via inhalation (e.g., oral and / or nasal inhalation (e.g., via nebulizer or spray)), via injection (e.g., intravenously, intra-arterial, subdermally, intraperitoneally, intramuscularly, and / or subcutaneously); via oral administration; or via topical administration (including topical (e.g., nasal) sprays, eye drops, and / or oral solutions). In some instances, the ADC or pharmaceutical composition is administered to the subject topically (e.g., an oral topical administration). In some instances, the ADC or pharmaceutical composition is administered to the subject intravenously. In some instances, the ADC or pharmaceutical composition is administered to the subject orally.
[0880] NUMBERED EMBODIMENTSAttorney Docket No. 58285-0010WO1
[0881] Embodiment 1. An antibody-drug conjugate (ADC) comprising:
[0882] an antibody that binds to Porphyromonas gingivalis,' and
[0883] a linker comprising a covalent protein binding moiety and a self-immolative linker comprising a lysine, and
[0884] an antibiotic;
[0885] wherein the antibody comprises a heavy chain variable region (VH) comprising a VH complementarity determining region (VH CDR) 1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37; and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO: 10 or 38.
[0886] Embodiment 2. The ADC of embodiment 1, wherein the VH CDR1 comprises the sequence of SEQ ID NO:3, the VH CDR2 comprises the sequence of SEQ ID NO:4, the VH CDR3 comprises the sequence of SEQ ID NO:5, the VL CDR1 comprises the sequence of SEQ ID NO:6, the VL CDR2 comprises the sequence of SEQ ID NO:7, and the VL CDR3 comprises the sequence of SEQ ID NO: 8.
[0887] Embodiment 3. The ADC of embodiment 1, wherein the VH comprises the sequence of SEQ ID NO:37 and the VL comprises the sequence of SEQ ID NO:38.
[0888] Embodiment 4. The ADC of embodiment 1, wherein the VH comprises an amino acid sequence at least 80% identical to the sequence of any one of SEQ ID NOs: 29-32 and the VL comprises an amino acid sequence at least 80% identical to the sequence of any one of SEQ ID NOs:33-36.
[0889] Embodiment 5. The ADC of embodiment 1, wherein the VH comprises the sequence of any one of SEQ ID NOs:29-32 and the VL comprises the sequence of any one of SEQ ID NOs:33-36.
[0890] Embodiment 6. The ADC of embodiment 1, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33.
[0891] Embodiment 7. The ADC of embodiment 1, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:35.Attorney Docket No. 58285-0010WO1
[0892] Embodiment 8. The ADC of any one of embodiments 1 to 7, wherein the antibody is a Fab, a diabody. Fab’. F(ab’)2, Fv, a single-chain antibody, bivalent antibody, bispecific antibody, or peptibody.
[0893] Embodiment 9. The ADC of any one of embodiments 1 to 7, wherein the antibody is an immunoglobulin comprising a heavy chain (HC) and a light chain (LC).
[0894] Embodiment 10. The ADC of embodiment 9, wherein the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an amino acid other than lysine at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO: 172, optionally wherein the amino acid other than lysine at position 105 as numbered in the sequence of SEQ ID NO: 172 is an alanine.
[0895] Embodiment 11. The ADC of embodiment 1, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino sequence at least 80% identical to the sequence of SEQ ID NO:263 and the light chain comprises an amino sequence at least 80% identical to the sequence of SEQ ID NO:253,
[0896] Embodiment 12. The ADC of embodiment 1, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of any one of SEQ ID NOs: 245, 247, 249, 251, 261, 263, 265, and 267, and the light chain comprises the sequence of any one of SEQ ID NOs: 253, 255, 257, and 259.
[0897] Embodiment 13. The ADC of embodiment 1, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy' chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253.
[0898] Embodiment 14. The ADC of embodiment 1, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy’ chainAttorney Docket No. 58285-0010WO1
[0899] comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:257.
[0900] Embodiment 15. The ADC of any one of embodiments 1 to 14, wherein the self- immolative linker is:
[0901]
[0902] , wherein
[0903] is the point of attachment to the antibiotic, optionally wherein “ ” isthe point of attachment to an -NH2 of the antibiotic, optionally wherein the antibiotic is sitafloxacin and is the point of attachment to the -NH2 of sitafloxacin;
[0904] LAis a bond
[0905]
[0906] LBis a bond
[0907]
[0908] indicates the point of attachment to
[0909]
[0910]
[0911] selected from phenylene, thiazolylene, and triazolylene;
[0912] R1and R2are independently selected from hydrogen and C1-C6 alkyl;
[0913] K is Lysine;
[0914] Z is an amino acid, optionally wherein Z is serine, asparagine, glycine, alanine, or other small, polar or acidic amino acid, optionally wherein Z is serine; and
[0915] is the point of attachment to the covalent protein binding moiety.
[0916] Embodiment 16. The ADC of embodiment 15, wherein the self-immolative linker is
[0917]
[0918] Embodiment 17. The ADC of embodiment 15 or 16, wherein the self-immolative linker is
[0919]
[0920] Attorney Docket No. 58285-0010WO1
[0921] Embodiment 18. The ADC of any one of embodiments 15 to 17, wherein Z is serine.
[0922] Embodiment 19. The ADC of any one of embodiments 15 to 18, wherein the covalent
[0923] protein binding moiety is selected from the group consisting
[0924]
[0925]
[0926] ; is the point of attachment to Z of the self- immolative linker;
[0927] indicates the point of attachment to a cysteine residue of the antibody; and n and m is an integer from 1 -20.
[0928] Embodiment 20. The ADC of any one of embodiments 15 to 19, wherein the covalent
[0929] protein binding moiety
[0930]
[0931] , wherein
[0932]
[0933] is the point of attachment to Z of the self-immolative linker;
[0934] indicates the point of attachment to a cysteine residue of the antibody; and wherein n is 5.
[0935] Embodiment 21. The ADC of any one of embodiments 1 to 14, wherein the ADC comprises the structure:
[0936]
[0937] (Formula I),
[0938] wherein Q is 1 to 14. wherein the drug is the antibiotic.Attorney Docket No. 58285-0010WO1
[0939] Embodiment 22. The ADC of any one of embodiments 1 to 14, wherein the ADC comprises the structure:
[0940]
[0941] (Formula II)
[0942] wherein Q is 1 to 14. wherein the drug is the antibiotic; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0943] Embodiment 23. The ADC of any one of embodiments 1 to 22, wherein the antibiotic treats a gram-negative bacterial infection.
[0944] Embodiment 24. The ADC of any one of embodiments 1 to 22, wherein the antibiotic treats a gram-positive bacterial infection.
[0945] Embodiment 25. The ADC of any one of embodiments 1 to 22, wherein the antibiotic is a fluoroquinolone.
[0946] Embodiment 26. The ADC of any one of embodiments 1 to 22, wherein the antibiotic is sitafloxacin.
[0947] Embodiment 27. The ADC of any one of embodiments 1 to 14, comprisingAttorney Docket No. 58285-0010WO1
[0948]
[0949] wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0950] Embodiment 28. The ADC of any one of embodiments 22, 25, and 27, wherein Q has a value from 3 to 5.
[0951] Embodiment 29. The ADC of embodiment 1, wherein the antibiotic is sitafloxacin, and wherein the ADC comprises:
[0952]
[0953] wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0954] Embodiment 30. The ADC of embodiment 1, wherein the antibiotic is sitafloxacin, and wherein the ADC comprises:
[0955]
[0956] Attorney Docket No. 58285-0010WO1
[0957] wherein Q is 1 to 14, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
[0958] Embodiment 31. A pharmaceutical composition, comprising the ADC of any one of embodiments 1 to 30, and a pharmaceutically acceptable carrier.
[0959] Embodiment 32. A linker-payload comprising: a linker comprising a covalent protein binding moiety and a self-immolative linker comprising a lysine, and a payload, wherein the payload is an antibiotic; wherein
[0960] (a) the self-immolative linker is
[0961]
[0962] is the point of attachment to the antibiotic, optionally wherein
[0963]
[0964] isthe point of attachment to an -NH2 of the antibiotic;
[0965] R1and R1are independently selected from hydrogen and C1-C6 alkyl;
[0966] 0 — is a ring selected from phenylene, thiazolylene, and triazolylene;
[0967] K is Lysine;
[0968] Z is a natural amino acid, optionally wherein Z is serine, asparagine, glycine, alanine, or other small, polar or acidic amino acid, optionally wherein Z is serine; and
[0969] is the point of attachment to the covalent protein binding moiety; and
[0970] (b) the covalent protein binding moiety is selected from the group consisting of
[0971]
[0972] the point of attachment to Z of the self-immolative linker;
[0973] indicates the point of attachment to a cysteine residue of the antibody; and n and m is an integer from 1 -20.
[0974] Embodiment 33. An antibody drug-conjugate (ADC) comprising the linker-payload of embodiment 32.Attorney Docket No. 58285-0010WO1
[0975] Embodiment 34. A pharmaceutical composition comprising the ADC of embodiment 33 and a pharmaceutically acceptable earner.
[0976] Embodiment 35. A method of making the ADC of any one of embodiments 1 to 30 and 33, the method comprising (a) culturing a cell producing the antibody, (b) isolating the antibody, (c) reducing the isolated antibody, and (c) conjugating the reduced, isolated antibody to the linker comprising the covalent protein binding moiety, the self- immolative linker comprising a lysine, and an antibiotic; optionally wherein the method further comprises formulating the ADC as a sterile pharmaceutical composition.
[0977] Embodiment 36. A method of treating aP. gingivalis infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of embodiments 1 to 30 and 33; and optionally wherein the subject is a human.
[0978] Embodiment 37. A method of treating a condition, disorder, or disease associated with a P. gingivalis infection, or symptoms thereof, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of embodiments 1 to 30 and 33; optionally wherein the condition, disorder, or disease associated with a P. gingivalis infection is peri-implantitis, periodontal disease, bone loss associated with periodontal disease, an age-related cognitive disorder, or a longevity- or age-related disorder; and optionally wherein the subject is a human.
[0979] Embodiment 38. A method of treating peri-implantitis, periodontal disease, or bone loss associated with periodontal disease in a subject in need thereof, the method comprising administering to the subj ect a therapeutically effective amount of the ADC of any one of embodiments 1 to 30 and 33. wherein the subject has aP. gingivalis infection, and optionally wherein the subject is a human.
[0980] Embodiment 39. A method of treating age-related cognitive disorder, or a longevity- or age-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of embodiments 1 to 30 and 33, wherein the subject has aP. gingivalis infection, and optionally wherein theAttorney Docket No. 58285-0010WO1
[0981] subject is a human, optionally wherein the age-related cognitive disorder is a dementia or Alzheimer’s disease.
[0982] Embodiment 40. A method of treating a systemic inflammatory disease associated with periodontitis or associated with aP. gingivalis infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of embodiments 1 to 30 and 33, wherein the subject has aP. gingivalis infection, and optionally wherein the subject is a human, optionally wherein the systemic inflammatory' disease associated with periodontitis or associated with aP. gingivalis infection is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease.
[0983] Embodiment 41. A method of delivering an antibiotic to a subj ect in need thereof, the method comprising administering to the subject the ADC of any one of embodiments 1 to 30 and 33, optionally wherein the subject is a human.
[0984] The following are examples of the practice of the invention. They are not to be construed as limiting the scope of the invention in any way.
[0985] EXAMPLES
[0986] The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art can develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.
[0987] Methods and Materials for Examples 1-3 and 9-10
[0988] HPLC Method A: SEC chromatography analysis ofH5 (HC SEQ ID NO:263, LC SEQ ID NO:253) and H5-ADC (HC SEQ ID NO:263, LC SEQ ID NO:253) was performed with an Agilent 1260 Infinity' II HPLC system with an ACQUITY UPLC® Protein BEH SEC column, 200, 1.7 pm, 4.6 mm X 150 mm run at a flow rate of 0.25 mL / min with detection at 280 nm at room temperature. Eluent was 200 mM potassium phosphate with 250 mM potassium chloride at pH 6.95nm with a runtime of 15 min. Each sample w as about 3 pg inj ected in the column.Attorney Docket No. 58285-0010WO1
[0989] HPLC Method B: LC / MS analysis of H and H5-ADC was performed with an Sciexn, Triple ToF 6600 detector and an XBridge® Protein BEH C4 column. 300A, 3.5 pm, 2.1 mm
[0990] X 50 mm.
[0991] Method: 0.25 mL / min; 280 nm; 80°C
[0992] Solvent A: water with 0.1%FA
[0993] Solvent B: acetonitrile with 0.1 %FA
[0994] Gradient: 5-90% Solvent B over 7.5 min
[0995] EXAMPLE 1. SYNTHESIS OF MALEIMIDE-Cs-SER-LYS-PABC-SITAFLOXACIN
[0996] (3326-01)
[0997]
[0998] Using standard amide coupling conditions with coupling reagent Ethyl l,2-dihydro-2-ethoxy quinoline- 1 -carboxylate (EEDQ), 6-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)hexanoic
[0999] acid was coupled with tert-butyl ((S)-2-((S)-2-amino-3-(tert-butoxy)propanamido)-3-((4-(hy droxy methyl)pheny l)amino)-3 -oxopropy l)trimethy I -U-azanecarboxy late to afford
[1000] intermediate A, which was activated by treatment with bis(4-nitrophenyl)carbonate (bis-PNPC) then treated with sitafloxacin to give protected 3326-01. Removal of the BOC and O-t-butoxyl protecting groups with trifluoroacetic acid (TFA) provided 3326-01. The final deprotection step was performed at room temperature with various volume ratios of TFA-to-solvent as shown in Table 3 below'. The final product was purified by preparative HPLC.
[1001] NMR and mass spectrum were consistent with the structure of 3326-01.
[1002] Table 3. Deprotection conditions and yield of 3326-01
[1003]
[1004] Attorney Docket No. 58285-0010WO1
[1005]
[1006] *DCM = di chloromethane; **TIPS =triisopropylsilane
[1007] EXAMPLE 2. GENERATION OF ANTIBODY-DRUG CONJUGATE
[1008] Compound 3326-01 was conjugated to H5 antibody by pre-treating the antibody with TCEP (tris(2-carboxyethyl)phosphine) to expose free thiol groups which were then reacted with the mal eimide moiety of 3326-01. The Drug-Antibody -Ratio (DAR) was determined by LC / MS, and the final oligomerization state was determined by analytical SEC.
[1009] In brief, the antibody H5 (concentration about 5 mg / mL in 1XPBS, pH 7.4; HC SEQ ID NO:263, LC SEQ ID NO:253) was treated with 4-4.7 molar equivalents (per molar equivalent of antibody) of TCEP at 37°C for 2 hours, then 3326-01 (8-20 molar equivalents / relative to H5) was added, and the mixture was held at 4°C for 2 hours. The treated H5 was then subjected to dialysis in PBS buffer to remove excess 3326-01. After dialysis, the conjugated H5 was filtered, and the level of conjugation w as determined by LC / MS. Using the foregoing procedure, a small scale batch was performed by H5 reduction with 4.7 equivalents of TCEP followed by treatment with 20 equivalents of 3326-01 to provide a DAR of 5.0. A repeat batch on larger scale was performed using 4.0 equivalents of TCEP followed by 8 equivalents of 3326-01, which after dialysis was determined to have DAR at 3.8. A third batch was prepared using 4 equivalents of TCEP and 8 equivalents of 3326-01; the third batch had a DAR at 3.3 after removal of aggregates with a total yield of 9.2 mg of H5-ADC obtained. FIGs. 1A-1C show the MS analysis, which was compared with the values tabulated for conjugate masses shown in the Table 4. Antibody and H5-ADC was analyzed by HPLC. The original H5 antibody, which had undergone 1 initial freeze-thaw cycle and storage at 4°C for >2 weeks was about 90% (see FIG. 2). After conjugation and storage overnight at 4°C, H5-ADC was determined to have a purity of 82.1 % with -18% overall aggregates / impurities compared to - 8% aggregates / impurities in the original H5 (see FIG. 3)
[1010] Table 4. Calculated mass values of 3326-01 conjugates to H5 antibody with 1-4 payloads added per antibody (PLX value). H and L refer to heavy and light chain, respectively.
[1011]
[1012] Attorney Docket No. 58285-0010WO1
[1013]
[1014] EXAMPLE 3. STABILITY OF H5 ANTIBODY AND H5-ADC
[1015] SEC Chromatography: The stability of H5 antibody and H5-ADC was evaluated by analytical SEC after several freeze-thaw cycles. The monomer content of original H5 antibody (after 1 freeze-thaw cycle, and stored at 4°C > 2 week) was ~ 90% before additional freeze-thaw cycles, and remained similar throughout the tests of the freeze-thaw cycles as shown in Table 5.
[1016] Table 5. SEC purity of EI5 antibody after freeze-thaw cycles
[1017]
[1018] The stability of H5 ADC after storage at 4°C ~1 week before the stability test was evaluated and found to be ~ 80% before freeze-thaw cycle, and remained similar throughout the tests of the freeze-thaw cycles. Table 6 shows the results of the freeze-thaw cycles on H5-ADC purity.
[1019] Table 6. SEC purity of H5-ADC after freeze-thaw cycles
[1020]
[1021] Attorney Docket No. 58285-0010WO1
[1022]
[1023] Coomassie blue gel analysis: Each sample of H5 or H5-ADC after a freeze-thaw cycle was evaluated by Western blot analysis. About 1 pg of sample was treated without reducing agent and heated at 70 °C for 10 minutes before loading onto the gel.
[1024] Based on the Coomassie blue stained gel, only one major band was observed from H5 samples after each freeze-thaw cycle (FIG. 4). Similarly, H5-ADC samples after each freezethaw cycle were observed staying the same, since all bands were observed similarly without aggregations.
[1025] LC / MS analysis: Each sample of H5 or H5-ADC after a freeze-thaw cycle was evaluated by LC / MS HPLC method B. For H5, there were no major difference observed after each freeze-thaw cycle up to 4 in either the deglycoslyated or the deglycoslyated and reduced samples (see FIGs. 5A-5D). Similarly, For H5-ADC, there were no major difference observed after each freeze-thaw cycle up to 4 in either the deglycoslyated or the deglycoslyated and reduced samples (see FIG. 6A-6D). The DAR values remained relatively stable through the freeze-thaw cycles as shown in Table 7.
[1026] Table 7. DAR value after freeze-thaw cycle for H5-ADC
[1027]
[1028] EXAMPLE 4: LYSYL ENDOPEPTIDASE CLEAVAGE ACTIVITY
[1029] This example investigates the lysyl endopeptidase cleavage activity against the payload linker.
[1030] Briefly, serial dilutions of lysyl endopeptidase (Irvine Scientific, Cat. No. 121-05063; 5 pL / well 2X protein) and of substrate (5 pL / well 2X substrate) were incubated at 37°C for 60 minutes. Substrates included 3326-01 and 3361-01, and sitafloxacin substate was used as a calibration curve. Reactions were quenched with 40 pL 50 / 50 ACN / water. SubstrateAttorney Docket No. 58285-0010WO1
[1031] (3326-01, 3361-01, and sitafloxacin) peaks were measured by mass spectrometry (FIGs. 7-8). As the enzyme concentration increased, peak areas for payload-linker decreased and for sitafloxacin increased, indicating the lysyl endopeptidase cleaved the payload-linker (FIGs.
[1032] 7-8).
[1033] EXAMPLE 5: KALLIKREIN 13 CLEAVAGE ACTIVITY
[1034] This example investigates the kallikrein 13 cleavage activity against the pay load linker. Kallikrein 13 is a serine protease primarily found in salivary glands.
[1035] Briefly, serial dilutions of kallikrein 13 (Biotechne R& D Systems, Cat. No. 2625-SE-010; 5 pL / well 2X protein) and of substrate (5 pL / well 2X substrate) were incubated at 37°C for 30 or 60 minutes. Substrates included Boc-Val-Pro-Arg-AMC Fluorogenic peptide substrate ("control peptide”; R& D Systems Catalog # ES011), H5-CUR-3326 ADC, and sitafloxacin. Reactions were quenched with 40 pL 50 / 50 ACN / water. Substrate (control peptide, H5-CUR-3326, or sitafloxacin) peaks were measured by fluorescence (FIGs. 9-11).
[1036] For control peptide, an increase in fluorescence was observed over time due to cleavage of the peptide by two different kallikrein 13 concentrations (750 and 375 ng / mL) (FIG. 9) Kallikrein 13 induced cleavage of ADC CUR-3326-01 was very low, less than 1% of the ADC substrate was cleaved (FIGs. 10-11). Km was higher than 12.6 pM - highest ADC test concentration.
[1037] EXAMPLE 6: ADC INTERNALIZATION
[1038] This example investigates internalization of the ADC into primary gingival keritinocytes. Briefly, primary gingival keratinocytes were harvested and seeded in a 384-well plate and incubated overnight at 37°C / 5% CO2 at 1500 cells per well. The following day, cells were pre-stained with 500 nMCellTracker Green for cellular identification and lOOnM SYTOX Orange for cytotoxicity for 30 minutes. Antibodies were conjugated with Fabfluor-pH Antibody Labeling Dyes according to the vendor protocol and serially diluted to create a two fold, 10-point dose response with atop concentration of 5 pg / mL. Antibodies used were: human EGFR Antibody (cetuximab, R& D Systems MAB9577), anti-CD71 (Sigma SAB4700520), human IgGl Isotype Control (Novus DDXCH01P100), H5 (HC SEQ ID NO:263, LC SEQ ID NO:253), and H5-3326-01. Labeled antibodies were added to the cells and the plate was imaged on the Revvity Opera Phenix every' hour for a total of 24 hours: 40X water objective, 37°C. 5% CO2 with humidity; brightfield, digital phase contrast.Attorney Docket No. 58285-0010WO1
[1039] green channel (488 ex.), near red channel (561 ex.), far red channel (640 ex.); 4 fields per well, 3 z-stacks. Fabluor spot intensity over time and area under curve were graphed for each antibody (FIGs. 12-16). FIG. 17 compares the AUC for each antibody.
[1040] Cetuximab (FIGs. 12A-12B) and anti-CD71 (FIGs. 13A-13B) antibodies were consistently well internalized by the primary gingival keratinocytes, while the H5 antibody (FIGs. 15A-15B), the conjugated H5 ADC (H5-3326-01) (FIGs. 16A-16B), and the negative control of the IgGl isotype (FIGs. 14A-14B) were not internalized significantly. Without being bound by any particular theory, these data suggest the antibody and the ADC are not internalized by the mouth cells (the primary gingival keratinocytes) and, thus, will be available to attack Porphyromonas gingivalis in the mouth.
[1041] EXAMPLE 7: GINGIPAIN CLEAVAGE ACTIVITY
[1042] This example investigates gingipain-mediated cleavage of the H5-CUR-3361-01 ADC, the CUR-3361-01 linker-payload, or a synthetic peptide control (N-p-Tosyl-Gly-Pro-Lys-p-nitroanilide). Briefly. P. gingivalis was cultured in tryptic soy broth media. Culture media was centrifuged and gingipain fractions were tested for cleavage of the H5-CUR-3361-01 ADC, the CUR-3361-01 linker-payload, or a synthetic peptide control. The gingipain fraction cleaved each of the H5-CUR-3361-01 ADC, the CUR-3361-01 linker-payload, and the synthetic peptide control.
[1043] EXAMPLE 8: ARGININE-SPECIFIC GINGIPAIN CLEAVAGE ACTIVITY
[1044] To test cleavage of an arginine-containing linker described herein, e.g., a linker of Formula XIV or XVI, or linker-payload comprising the same, or an ADC described herein comprising the same, P. gingivalis is cultured in tryptic soy broth media. Culture media is centrifuged and gingipain fractions are tested for cleavage of the linker, the ADC, or a synthetic peptide control. Alternatively, or additionally, an assay as described in Example 4. above, is performed using an arginine endopeptidase (instead of a lysyl endopeptidase).
[1045] To test the specificity of cleavage of the arginine-containing linker, or the linkerpayload comprising the same, or the ADC comprising the same, a kallikrein 13 cleavage activity assay is performed as described in Example 5.
[1046] EXAMPLE 9: GENERATION OF H5 ANTIB ODY-METRONID AZOLE
[1047] CONJUGATEAttorney Docket No. 58285-0010WO1
[1048] An antibody-metronidazole conjugate was prepared on both small and large scale. FIG. 18 is a scheme depicting the preparation of the antibody-metronidazole conjugate. The small scale conjugation used 0.6 mg of H5 antibody (concentration about 5 mg / mL in 1XPBS, pH 7.4; HC SEQ ID NO:263, LC SEQ ID NO:253), which was reduced with 3.5 equivalents of tris(2-carboxyethyl)phosphine (TCEP) at 37 °C for 2 hours to expose thiol groups which were reacted with 8 equivalents of the linker-metronidazole fragment at 4 °C for 2 hours. The level of conjugation was determined by LC / MS. The total drug antibody ratio (DAR) was 4.3. A repeat batch on 10 mg scale was performed using 3.5 equivalents of TCEP follow ed by 8 equivalents of the linker-metronidazole fragment, which after dialysis was determined to have a DAR at 4.4. In the large scale experiment after conjugation, after dialyzing twice with DPBS at 4 °C overnight, the conjugated H5 was concentrated using a 10 kDa MWCO centrifugal concentrator, and the impurities were centrifuged down before aliquoting. The mass of product obtained w as 15.7 mg. All products had undergone deglycosylation with PNGase at 50 °C for 0.5 hour; half of deglycosy lated materials were used as the non-reduced samples, and another half of the materials were further reduced with 20 mM DTT as the reduced samples. FIGS. 19A-19C show the MS analysis for the small scale experiment, which was compared with the values tabulated for conjugate masses shown in Table 8. FIG. 19A is a representative triple-ToF mass spectrum (ToF MS) of the small scale metronidazole H5-ADC. FIG. 19B is an enlarged version of the heavy chain data of FIG. 19A. FIG. 19C is an enlarged version of the light chain data of FIG. 19A. FIGS. 20A-20C show the MS analysis for the large scale experiment, which was compared with the values tabulated for conjugate masses shown in Table 8. FIG. 20A is a representative triple-ToF mass spectrum (ToF MS) of the large scale metronidazole H5-ADC. FIG. 20B is an enlarged version of the heavy chain data of FIG. 20A. FIG. 20C is an enlarged version of the light chain data of FIG. 20A.
[1049] Table 8. Calculated mass values of metronidazole conjugates to H5 antibody w ith 1-4 payloads added per antibody (PLX value). H and L refer to heavy and light chain, respectively.
[1050]
[1051] Attorney Docket No. 58285-0010WO1
[1052] The original H5 antibody was about 93% pure (see FIG. 21A). After conjugation, the metronidazole H5-ADC was determined to have a purity of 95% with ~5% overall aggregates / impurities compared to ~ 7% aggregates / impurities in the original H5 (see FIG.
[1053] 21B)
[1054] EXAMPLE 10: STABILITY OF H5 ANTIBODY-METRONIDAZOLE CONJUGATE SEC Chromatography: The stability of H5 antibody and H5-ADC was evaluated by analytical SEC after several freeze-thaw cycles. The protein was stored at -80°C, and then quickly thawed. The thawed sample was taken and mixed with 1XPBS, and the rest of the sample was stored back to -80 ° C. This process was repeated up to 4 times. It was estimated 1.5 pg of each sample injected into analytical SEC column. No significant differences of peak area was observed from each F / T sample (see FIG. 22; F / T cycles show nearly the same purity, with plots largely overlapping / superimposed), and the conjugate is stable after up to 4 freeze- th aw cycles.
[1055] EXAMPLE 11: HYDROPHOBIC INTERACTION CHROMATOGRAPH (HIC) ANALYSIS
[1056] Hydrophobic interaction chromatography (HIC) w as also tested for its aptitude to measure DAR of the antibody-metronidazole conjugate. The antibody before conjugation was subjected to hydrophobic interaction chromatography using an Agilent 1260 Infinity II instrument loaded with a TSKgel Butyl-NRP column, 2.5 pm, 4.6 mm X 35 mm column at a flow rate of 0.8 mL / min and wavelengths of 254, 280, and 318 nm at 30°C. Mobile Phase A: 25 mM sodium phosphate with 1.5 M ammonium sulphate at pH 7.4 over 15 min; Mobile phase B: 25 mM sodium phosphate with 10% IP A at pH 7.4. FIG. 23A is an HIC chromatograph of H5 antibody. FIG 23B is an expanded view of the plot in FIG. 23A. Tw o peaks were observed. The same HIC method was repeated on antibody-metronidazole conjugate (see FIGS. 24A-24B). Five peaks were observed. The DAR per peak = % area * DAR#. Table 9 shows the DAR#, % area, and DAR per peak. The total DAR = sum of DAR / peak = 4.9.
[1057] Table 9. DAR#, % area, and DAR per peak for antibody-metronidazole conjugate.
[1058]
[1059] Attorney Docket No. 58285-0010WO1
[1060]
[1061] The free payload linker was determined in the final sample using an Agilent 1290 Infinity II loaded with an Agilent ZORBAX 300SB-C8, 1.8 pm, 2.1 mm X 100 mm column using a flow rate of 0.4 mL / min and wavelengths of 254, 280, and 318 nm at 70°C. Mobile phase A: water with 0.1% trifluoroacetic acid (TFA); Mobile phase B: acetonitrile with 0.1% TFA with a gradient from 0-90% mobile phase B over 8 min. The quenched payload was prepared by quenching 0.5 mM of payload with 30 rnM A-acety I - / .-cysteine in 25% DMSO at RT for 30 min; diluting the quenched payload with MeOH; then injecting 10 pL into the column. The concentrations of pay load were tested at 0.1, 0.25, 0.5, 1, 2, 5, and 10 pM; a standard curve of pay load linker was measured at 318 nm and plotted (FIG. 25C); and based on the quantity measured at 318 nm, 2.1 pM (~2%) of unbound payload was not removed from the final sample. FIG. 25A is a chromatograph of pure payload linker, and FIG. 25B is a chromatograph of antibody-metronidazole conjugate, showing a much lower amount of the free payload linker relative to FIG. 25A. FIG. 25C is a standard calibration curve for converting chromatographic peak areas to analyte concentrations.
[1062] EXAMPLE 12: RECOMBINANT GINGIPAIN B HEXAHISTIDINE PROTEASE CLEAVAGE ACTIVITY
[1063] An investigation of recombinant gingipain B hexahistidine protease (RgpB6H) cleavage activity against a capped metronidazole payload linker, shown below, was performed.
[1064]
[1065] Serial dilutions (0, 25, 50, and 100 pM; 5 uL / well, 384 well format) of linker were quenched without enzyme (negative control) and 50 nM RgpB6H at time points of 30, 60, and 90 minutes. The assay buffer was 100 mM Tris HC1, 2.5 mM CaC12, 75 mM NaCl,Attorney Docket No. 58285-0010WO1
[1066] 0.01% NaN3, 10 mM L-cysteine. FIG. 26A is a substrate peak value table comparing peak values for the negative control and 50 nM RgpB6H at different linker concentrations and with 100 pM metronidazole. FIG. 26B is a plot of substrate peaks in samples lacking enzyme vs. linker concentration at different times. FIG. 26C is a plot of substrate peaks in samples including 50 nM RgpB6H vs. linker concentration at different times. These results show that that most of the payload linker is depleted in the first 30 minutes of incubation with enzyme, thus demonstrating the proteolytic activity of RgpB6H against the capped payload linker. FIG. 27A is a product peak value table comparing peak values for the negative control and 50 nM RgpB6H at different linker concentrations and 100 pM metronidazole; and metronidazole concentrations observed for the negative control and 50 nM RgpB6H at different linker concentrations and 100 pM metronidazole. FIG. 27B is a metronidazole calibration curve. FIG. 27C is a plot show ing metronidazole concentration in samples including 50 nM RgpB6H vs. linker concentration at different times. These results show that (1) metronidazole levels do not degrade over time, nor are they degraded in the presence of enzyme (see Row E); (2) there is no increase in metronidazole levels over time for sample wells with linker and enzyme, which is believed to suggest that not all the linker is being converted to metronidazole; and (3) for 100 pM linker samples. -60-65 pM metronidazole product is observed, which is a 60% conversion.
[1067] The cleavage activity of RgpB6H on the payload linker and metronidazole-antibody conjugate were then tested at substrate concentrations of 28.78 pM and 9.59 pM. Quenching was performed after 30 minutes. FIG. 28A shows the linker peaks observed in w ells lacking enzyme, wells treated with 25 nM RgpB6H. and wells treated with 50 nM RgpB6H; and FIG. 28B is a bar graph depicting the data in FIG. 28A. The w ells treated with RgpB6H exhibited nearly full depletion of both the payload linker and the conjugate, thus demonstrating a very high cleavage aptitude of RgpB6H on the substrates. FIG. 29A is a peak value table showing the metronidazole peaks observed in wells lacking enzyme, wells treated with 25 nM RgpB6H, and wells treated with 50 nM RgpB6H. FIGS. 29B-29C are metronidazole concentration tables showing the concentration of metronidazole in wells lacking enzy me, wells treated with 25 nM RgpB6H, and wells treated with 50 nM RgpB6H.
[1068] FIG. 29D is a bar graph depicting the data in FIG. 29A. The results show that the wells including 28.78 pM linker that were exposed to RgpB6H yielded about 8-9 pM metronidazole, which is an approximately 28% conversion. The wells including 28.78 pM conjugate yielded about 52-55 pM metronidazole, which corresponds to a nearly 50%Attorney Docket No. 58285-0010WO1
[1069] conversion based on the DAR of 4.4 As such. RgpB6H has a high catalytic activity' on the payload linker and the conjugate.
[1070] SEQUENCES KB001 H1-H16 VH consensus QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWXiGMIWGGGSS DYNSALKSRX2TISX3DTSKNQX4SLKLSSVTAADTAX5YYCARNGNFYAMDYWGQG TLVTVSS, wherein Xi is I or L, X2 is any naturally occurring amino acid, X3 is any naturally occurring amino acid, X4 is any naturally occurring amino acid, and X5 is any naturally occurring amino acid (SEQ ID NO:37)
[1071] KB001 Hl -Hl 6 VL consensus EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPX1LX2IYSTSNLASG IPX3RFSGSGSGTDX4TLTISRLEPEDFAX5YYCHQYHHSPYIYTFGGGTKLEIK, wherein Xi is any naturally occurring amino acid, X2 is any naturally occurring amino acid, X3 is any naturally occurring amino acid, X4 is any naturally occurring amino acid, and X5 is any naturally occurring amino acid (SEQ ID NO:38)
[1072] Hl, H2, H3, H4 VH QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWIGMIWGGGSSD YNSALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARNGNFYAMDYWGQGTLV TVSS (SEQ ID NO:29)
[1073] H5. H6, H7, H8 VH QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWIGMIWGGGSSD YNSALKSRLTISKDTSKNQVSLKLSSVTAADTAVYYCARNGNFYAMDYWGQGTLV TVSS (SEQ ID NO:30)
[1074] H9. H1O. H11, H12 VH QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWLGMIWGGGSS DYNSALKSRLTISVDTSKNQVSLKLSSVTAADTAMYYCARNGNFYAMDYWGQGTL VTVSS (SEQ ID NO:31)
[1075] H13, H14, H15, H16VH QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWLGMIWGGGSS DYNSALKSRLTISKDTSKNQVSLKLSSVTAADTAMYYCARNGNFYAMDYWGQGTL VTVSS (SEQ ID NO: 32)
[1076] H1, H5, H9, H13 VL EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPRLLIYSTSNLASGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHHSPYIYTFGGGTKLEIK (SEQ ID NO:33)
[1077] H2, H6, H10, H14VL EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPQLWIYSTSNLASGI PDRFSGSGSGTDYTLTISRLEPEDFAVYYCHQYHHSPYIYTFGGGTKLEIK (SEQ ID NO:34)
[1078] H3, H7, H11, H15 VLAttorney Docket No. 58285-0010WO1
[1079] EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPQLWIYSTSNLASGIPDRFSGSGSGTDYTLTISRLEPEDFATYYCHQYHHSPYIYTFGGGTKLEIK (SEQ ID NO:35)
[1080] H4, H8, H12, H16VL EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPQLWIYSTSNLASGI PARFSGSGSGTDYTLTISRLEPEDFATYYCHQYHHSPYIYTFGGGTKLEIK (SEQ ID NO: 36)
[1081] HE H2, H3, H4 HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWIGMIWGGGSSD YNSALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARNGNFYAMDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:245)
[1082] H1-K222A, H2-K222A, H3-K222A, H4-K222A HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWIGMIWGGGSSD YNSALKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARNGNFYAMDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDATHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:261)
[1083] H5. H6, H7, H8 HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWIGMIWGGGSSD YNSALKSRLTISKDTSKNQVSLKLSSVTAADTAVYYCARNGNFYAMDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 247)
[1084] H5-K222A, H6-K222A, H7-K222A, H8-K222A HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWIGMIWGGGSSD YNSALKSRLTISKDTSKNQVSLKLSSVTAADTAVYYCARNGNFYAMDYWGQGTLV TVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFP AVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDATHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSAttorney Docket No. 58285-0010WO1
[1085] DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:263)
[1086] H9. H10. Hll, H12 HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWLGMIWGGGSS DYNSALKSRLTISVDTSKNQVSLKLSSVTAADTAMYYCARNGNFYAMDYWGQGTL VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQS SGLYSLS SVVTVPS SSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 249)
[1087] H9-K222A, H10-K222A, Hl 1-K222A, H12-K222A HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWLGMIWGGGSS DYNSALKSRLTISVDTSKNQVSLKLSSVTAADTAMYYCARNGNFYAMDYWGQGTL VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDATHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:265)
[1088] H13, H14, H15, H16HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWLGMIWGGGSS DYNSALKSRLTISKDTSKNQVSLKLSSVTAADTAMYYCARNGNFYAMDYWGQGTL VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:251)
[1089] H13-K222A, H14-K222A, H15-K222A, H16-K222A HC QVQLQESGPGLVKPSETLSLTCTVSGFSLSIYSVHWIRQPPGKGLEWLGMIWGGGSS DYNSALKSRLTISKDTSKNQVSLKLSSVTAADTAMYYCARNGNFYAMDYWGQGTL VTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDATHTCPP CPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVH NAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO:267)
[1090] Hl, H5, H9, H13 LC EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPRLLIYSTSNLASGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYCHQYHHSPYIYTFGGGTKLEIKRTVAAPSVFAttorney Docket No. 58285-0010WO1
[1091] IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:253) H2. H6, H10, H14 LC EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPQLWIYSTSNLASGI PDRFSGSGSGTDYTLTISRLEPEDFAVYYCHQYHHSPYIYTFGGGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:255) H3. H7, Hl 1, H15 LC EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPQLWIYSTSNLASGI PDRFSGSGSGTDYTLTISRLEPEDFATYYCHQYHHSPYIYTFGGGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:257) H4, H8, H11. H16 EIVLTQSPGTLSLSPGERATLSCTASSSVSSSFLHWYQQKPGQAPQLWIYSTSNLASGI PARFSGSGSGTDYTLTISRLEPEDFATYYCHQYHHSPYIYTFGGGTKLEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:259) VH / HC signal peptide
[1092] MGWSCIILFLVATATGVHS (SEQ IDNO:26)
[1093] VL / LC signal peptide
[1094] MGWSCIILFLVATATGVHS (SEQ IDNO:27)
[1095] KB001 Epitope
[1096] YTYTVYRDGTKIK (SEQ ID NO:39)
[1097] KB001 Epitope
[1098] YCVEVKYTAGVSPK (SEQ ID NO:40)
[1099] Exemplary RgpA from P. gingivalis MKNLNKFVSIALCSSLLGGMAFAQQTELGRNPNVRLLESTQQSVTKVQFRMDNLKF TEVQTPKGMAQVPTYTEGVNLSEKGMPTLPILSRSLAVSDTREMKVEVVSSKFIEKK NVLIAPSKGMIMRNEDPKKIPYVYGKSYSQNKFFPGEIATLDDPFILRDVRGQVVNFA PLQYNPVTKTLRIYTEITVAVSETSEQGKNILNKKGTFAGFEDTYKRMFMNYEPGRY TPVEEKQNGRMIVIVAKKYEGDIKDFVDWKNQRGLRTEVKVAEDIASPVTANAIQQ FVKQEYEKEGNDLTYVLLIGDHKDIPAKITPGIKSDQVYGQIVGNDHYNEVFIGRFSC ESKEDLKTQIDRTIHYERNITTEDKWLGQALCIASAEGGPSADNGESDIQHENVIANL LTQYGYTKIIKCYDPGVTPKNIIDAFNGGISLANYTGHGSETAWGTSHFGTTHVKQLT NSNQLPFIFDVACVNGDFLFSMPCFAEALMRAQKDGKPTGTVAIIASTINQSWASPM RGQDEMNEILCEKHPNNIKRTFGGVTMNGMFAMVEKYKKDGEKMLDTWTVFGDP SLLVRTLVPTKMQVTAPAQINLTDASVNVSCDYNGAIATISANGKMFGSAVVENGT ATINLTGLTNESTLTLTVVGYNKETVIKTINTNGEPNPYQPVSNLTATTQGQKVTLK WDAPSTKTNATTNTARSVDGIRELVLLSVSDAPELLRSGQAEIVLEAHDVWNDGSG YQILLDADHDQYGQVIPSDTHTLWPNCSVPANLFAPFEYTVPENADPSCSPTNMIMD GTASVNIPAGTYDFAIAAPQANAKIWIAGQGPTKEDDYVFEAGKKYHFLMKKMGSG DGTELTISEGGGSDYTYTVYRDGTKIKEGLTATTFEEDGVAAGNHEYCVEVKYTAG VSPKVCKDVTVEGSNEFAPVQNLTGSAVGQKVTLKWDAPNGTPNPNPNPNPNPNPGAttorney Docket No. 58285-0010WO1
[1100] TTTLSESFENGIPASWKTIDADGDGHGWKPGNAPGIAGYNSNGCVYSESFGLGGIGV LTPDNYLITPALDLPNGGKLTFWVCAQDANYASEHYAVYASSTGNDASNFTNALLE ETITAKGVRSPEAIRGRIQSTWRQKTVDLPAGTKYVAFRHFQSTDMFYIDLDEVEIKA NGKRADFTETFESSTHGEATAEWTTIDADGDGQGWLCLSSGQLDWLTAHGGTNVV SSFSWNGMALNPDNYLISKDVTGATKVKYYYAVNDGFPGDHYAVMISKTGTNAGD FTVVFEETPNGINKGGARFGLSTEADGAKPQSVWIERTVDLPAGTKYVAFRHYNCSD LNYILLDDIQFTMGGSPTPTDYTYTVYRDGTKIKEGLTETTFEEDGVATGNHEYCVE VKYTAGVSPKKCVNVTVNSTQFNPVKNLKAQPDGGDVVLKWEAPSAKKTEGSREV KRIGDGLFVTIEPANDVRANEAKVVLAADNVWGDNTGYQFLLDADHNTFGSVIPAT GPLFTGTASSDLYSANFEYLIPANADPVVTTQNIIVTGQGEVVIPGGVYDYCITNPEPA SGKMWIAGDGGNQPARYDDFTFEAGKKYTFTMRRAGMGDGTDMEVEDDSPASYT YTVYRDGTKIKEGLTETTYRDAGMSAQSHEYCVEVKYTAGVSPKVCVDYIPDGVAD VTAQKPYTLTVVGKTITVTCQGEAMIYDMNGRRLAAGRNTVVYTAQGGYYAVMV VVDGKSYVKKLAIK (SEQ ID N0:41)
[1101] Exemplary Kgp from P. gingivalis MRKLLLLTAASLLGVGLYAQSAKIKLDAPTTRTTCTNNSFKQFDASFSFNEVELTKVE TKGGTFASVSIPGAFPTGEVGSPEVPAVRKLIAVPVGATPVVRVKSFTEQVYSLNQYG SEKLMPHQPSMSKSDDPEKVPFVYNAAAYARKGFVGQELTQVEMLGTMRGVRIAA LTINPVQYDVVANQLKVRNNIEIEVSFQGADEVATQRLYDASFSPYFETAYKQLFNR DVYTDHGDLYNTPVRMLVVAGAKFKEALKPWLTWKAQKGFYLDVHYTDEAEVGT TNASIKAFIHKKYNDGLAASAAPVFLALVGDTDVISGEKGKKTKKVTDLYYSAVDG DYFPEMYTFRMSASSPEELTNIIDKVLMYEKATMPDKSYLEKVLLIAGADYSWNSQV GQPTIKYGMQYYYNQEHGYTDVYNYLKAPYTGCYSHLNTGVSFANYTAHGSETAW ADPLLTTSQLKALTNKDKYFLAIGNCCITAQFDYVQPCFGEVITRVKEKGAYAYIGSS PNSYWGEDYYWSVGANAVFGVQPTFEGTSMGSYDATFLEDSYNTVNSIMWAGNLA ATHAGN1GNITHIGAHYYWEAYHVLGDGSVMPYRAMPKTNTYTLPASLPQNQASYS IQASAGSYVAISKDGVLYGTGVANASGVATVSMTKQITENGNYDVVITRSNYLPVIK QIQVGEPSPYQPVSNLTATTQGQKVTLKWEAPSAKKAEGSREVKRIGDGLFVTIEPA NDVRANEAKVVLAADNVWGDNTGYQFLLDADHNTFGSVIPATGPLFTGTASSNLYS ANFEYLVPANADPVVTTQNIIVTGQGEVVIPGGVYDYCITNPEPASGKMWIAGDGGN QPARYDDFTFEAGKKYTFTMRRAGMGDGTDMEVEDDSPASYTYTVYRDGTKIKEG LTATTFEEDGVAAGNHEYCVEVKYTAGVSPKVCKDVTVEGSNEFAPVQNLTGSSVG QKVTLKWDAPNGTPNPNPNPNPNPGTTLSESFENGIPASWKTIDADGDGHGWKPGN APGIAGYNSNGCVYSESFGLGGIGVLTPDNYLITPALDLPNGGKLTFWVCAQDANYA SEHYAVYASSTGNDASNFTNALLEETITAKGVRSPKAIRGRIQGTWRQKTVDLPAGT KYVAFRHFQSTDMFYIDLDEVEIKANGKRADFTETFESSTHGEAPAEWTTIDADGDG QGWLCLS SGQLDWLTAHGGSNVVS SFSWNGMALNPDNYLISKDVTGATKVKYYY AVNDGFPGDHYAVMISKTGTNAGDFTVVFEETPNGINKGGARFGLSTEANGAKPQS VWIERTVDLPAGTKYVAFRHYNCSDLNYILLDDIQFTMGGSPTPTDYTYTVYRDGTN IKEGLTETTFEEYGVATGNHEYCVEVKYTAGVSPKKCVDVTVNSTQFNPVQNLTAE QAPNSMDAILKWNAPASKRAEVLNEDFENGIPASWKTIDAHGDGNNWTTTPPPGGS SFAGHNSAICVSSASHINFEGPQNPDNYLVTPELSLPGGGTLTFWVCAQDANYASEH YAVYASSTGNDASNFANALLEEVLTAKTVVTAPEAIRGTRAQGTWYQKTVQLPAGT KYVAFRHFGCTDFFWINLDDVVITSGNAPSYTYTIYRNNTQIASGVTETTYRDPDLAT GFYTYGVKVVYPNGESAIETATLNITSLADVTAQKPYTLTVVGKTITVTCQGEAMIY DMNGRRLAAGRNTVVYTAQGGHYAVMVVVDGKSYVEKLAVK (SEQ ID NO:42) Exemplary7HagA from P. gingivalisAttorney Docket No. 58285-0010WO1
[1102] MRKLNSLFSLAVLLSLLCWGQTAAAQGGPKTAPSVTHQAVQKGIRTSKVKDLRDPIP AGMARIILEAHDVWEDGTGYQMLWDADHNQYGASIPEESFWFANGTIPAGLYDPFE YKVPVNADASFSPTNFVLDGTASADIPAGTYDYVIINPNPGIIYIVGEGVSKGNDYVV EAGKTYHFTVQRQGPGDAASVVVTGEGGNEFAPVQNLQWSVSGQTVTLTWQAPAS DKRTYVLNESFDTQTLPNGWTMIDADGDGHNWLSTINVYNTATHTGDGAMFSKSW TASGGAKIDLSPDNYLVTPKVTVPENGKLSYWVSSQVPWTNEHYGVFLSTTGNEAA NFTIKLLEETLGSDKPAPMNLVKSEGVKLPAPYQERTIDLSAYAGQQVYLAFRHFNS TGIFRLYLDDVAVSGEGSSNDYTYTVYRDNVV1AQNLAATTFNQENVAPGQYNYCV EVKYTAGVSPKVCKDVTVEGSNEFAHVQNLTGSAVGQKVTLKWDAPNGTPNPNPG TTTLSESFENGIPASWKTIDADGDGNNWTTTPPPGGTSFAGHNSAICASSASYINFEGP QNPDNYLVTPELSLPNGGTLTFWVCAQDANYASEHYAVYASSTGNDASNFANALLE EVLTAKTVVTAPEAIRGTRVQGTWYQKTVQLPAGTKYVAFRHFGCTDFFWINLDDV EIKANGKRADFTETFE S STHGEAP AEWTTID ADGDGQGWLCLS S GQLDWLTAHGGT NVVASFSWNGMALNPDNYLISKDVTGATKVKYYYAVNDGFPGDHYAVMISKTGTN AGDFTVVFEETPNGINKGGARFGLSTEADGAKPQSVWIERTVDLPAGTKYVAFRHY NCSDLNYILLDDIQFTMGGSPTPTDYTYTVYRDGTKIKEGLTETTFEEDGVATGNHE YCVEVKYTAGVSPKECVNVTVDPVQFNPVQNLTGSAVGQKVTLKWDAPNGTPNPN PNPNPGTTTLSESFENGIPASWKTIDADGDGNNWTTTPPPGGTSFAGHNSAICASSAS YINFEGPQNPDNYLVTPELSLPNGGTLTFWVCAQDANYASEHYAVYASSTGNDASN FANALLEEVLTAKTVVTAPEAIRGTRVQGTWYQKTVQLPAGTKYVAFRHFGCTDFF WINLDDVEIKANGKRADFTETFES STHGEAP AEWTTID ADGDGQGWLCLS SGQLGW LTAHGGTNVVASFSWNGMALNPDNYLISKDVTGATKVKYYYAVNDGFPGDHYAV MISKTGTNAGDFTVVFEETPNGINKGGARFGLSTEADGAKPQSVWIERTVDLPAGTK YVAFRHYNCSDLNYILLDDIQFTMGGSPTPTDYTYTVYRDGTKIKEGLTETTFEEDG VATGNHEYCVEVKYTAGVSPKECVNVTVDPVQFNPVQNLTGSAVGQKVTLKWDAP NGTPNPNPNPNPGTTTLSESFENGIPASWKTIDADGDGNNWTTTPPPGGTSFAGHNSA ICASSASYINFEGPQNPDNYLVTPELSLPNGGTLTFWVCAQDANYASEHYAVYASST GNDASNFANALLEEVLTAKTVVTAPEAIRGTRVQGTWYQKTVQLPAGTKYVAFRHF GCTDFF WINLDDVEIKANGKRADFTETFES STHGEAP AEWTTID ADGDGQGWLCLS S GQLGWLTAHGGTNVVASFSWNGMALNPDNYLISKDVTGATKVKYYYAVNDGFPG DHYAVMISKTGTNAGDFTVVFEETPNGINKGGARFGLSTEADGAKPQSVWIERTVD LPAGTKYVAFRHYNCSDLNYILLDDIQFTMGGSPTPTDYTYTVYRDGTKIKEGLTET TFEEDGVATGNHEYCVEVKYTAGVSPKECVNVTVDPVQFNPVQNLTGSAVGQKVT LKWDAPNGTPNPNPNPNPGTTTLSESFENGIPASWKTIDADGDGNNWTTTPPPGGTS FAGHNSAICVSSASYINFEGPQNPDNYLVTPELSLPGGGTLTFWVCAQDANYASEHY AVYASSTGNDASNFANALLEEVLTAKTVVTAPEAIRGTRVQGTWYQKTVQLPAGTK YVAFRHFGCTDFFWINLDEVEIKANGKRADFTETFESSTHGEAP AEWTTID ADGDGQ GWLCLSSGQLDWLTAHGGTNVVASFSWNGMALNPDNYLISKDVTGATKVKYYYA VNDGFPGDHYAVMISKTGTNAGDFTVVFEETPNG1NKGGARFGLSTEADGAKPQSV WIERTVDLPAGTKYVAFRHYNCSDLNYILLDDIQFTMGGSPTPTDYTYTVYRDGTKI KEGLTETTFEEDGVATGNHEYCVEVKYTAGVSPKVCVNVTINPTQFNPVQNLTAEQ APNSMD AILKWNAP ASKRAEVLNEDFENGIP S S WKTID ADGDGNNWTTTPPPGGS SF AGHNSAICVSSASYINFEGPQNPDNYLVTPELSLPGGGTLTFWVCAQDANYASEHYA VYASSTGNDASNFANALLEEVLTAKTVVTAPEAIRGTRVQGTWYQKTVQLPAGTKY VAFRHFGCTDFFWINLDDVVITSGNAPSYTYTIYRNNTQIASGVTETTYRDPDLATGF YTYGVKVVYPNGESAIETATLNITSLADVTAQKPYTLTVVGKTITVTCQGEAMIYDM NGRRLAAGRNTVVYTAQGGHYAVMVVVDGKSYVEKLAVK (SEQ ID NO:43) Exemplary heavy chain constant regionAttorney Docket No. 58285-0010WO1
[1103] ASTKGP S VFPL AP S SKSTSGGTAALGCLVKDYFPEP VTVS WNSGALTS GVHTFP AVL QS SGLYSLS S V VTVP S S SLGTQTYICN VNHKP SNTKVDKKVEPKS CD ATHTCPPCP AP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSD GSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 172)
[1104] OTHER EMBODIMENTS
[1105] It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims
Attorney Docket No. 58285-0010WO1WHAT IS CLAIMED IS:
1. An antibody-drug conjugate (ADC) comprising:an antibody that binds to Porphyromonas gingivalis anda linker comprising a covalent protein binding moiety and a self-immolative linker comprising a lysine or arginine, andan antibiotic;wherein the antibody comprises a heavy chain variable region (VH) comprising a VH complementarity determining region (VH CDR) 1, a VH CDR2, and a VH CDR3 from the sequence of SEQ ID NO:9 or 37; and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3 from the sequence of SEQ ID NO: 10 or 38.
2. The ADC of claim 1, wherein the VH CDR1 comprises the sequence of SEQ ID NO: 3, the VH CDR2 comprises the sequence of SEQ ID NO:
4. the VH CDR3 comprises the sequence of SEQ ID NO:5, the VL CDR1 comprises the sequence of SEQ ID NO:6, the VL CDR2 comprises the sequence of SEQ ID NO: 7, and the VL CDR3 comprises the sequence of SEQ ID NO: 8.
3. The ADC of claim 1, wherein the VH comprises the sequence of SEQ ID NO:37 and the VL comprises the sequence of SEQ ID NO:38.
4. The ADC of claim 1, wherein the VH comprises an amino acid sequence at least 80% identical to the sequence of any one of SEQ ID NOs: 29-32 and the VL comprises an amino acid sequence at least 80% identical to the sequence of any one of SEQ ID NOs:33-36.
5. The ADC of claim 1, wherein the VH comprises the sequence of any one of SEQ ID NOs:29-32 and the VL comprises the sequence of any one of SEQ ID NOs:33-36.
6. The ADC of claim 1, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33.
7. The ADC of claim 1. wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:35.Attorney Docket No. 58285-0010WO18. The ADC of any one of claims 1 to 7, wherein the antibody is a Fab, a diabody, Fab’, F(ab’)2, Fv, a single-chain antibody, bivalent antibody, bispecific antibody, or peptibody.
9. The ADC of any one of claims 1 to 7, wherein the antibody is an immunoglobulin comprising a heavy chain (HC) and a light chain (LC).
10. The ADC of claim 9. wherein the heavy chain comprises an Fc region comprising an amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO: 172, wherein the Fc region comprises an amino acid other than lysine at position 105 as numbered according to the numbering as provided in the sequence of SEQ ID NO:
172. optionally wherein the amino acid other than lysine at position 105 as numbered in the sequence of SEQ ID NO: 172 is an alanine.
11. The ADC of claim 1, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises an amino sequence at least 80% identical to the sequence of SEQ ID NO:263 and the light chain comprises an amino sequence at least 80% identical to the sequence of SEQ ID NO:253,12. The ADC of claim 1, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of any one of SEQ ID NOs: 245, 247, 249, 251, 261, 263, 265, and 267, and the light chain comprises the sequence of any one of SEQ ID NOs: 253, 255, 257, and 259.
13. The ADC of claim 1. wherein the antibody is an immunoglobulin comprising a heavy’ chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253.
14. The ADC of claim 1, w herein the antibody is an immunoglobulin comprising a heavy' chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:257.
15. The ADC of any one of claims 1 to 14, wherein the self-immolative linker is:Attorney Docket No. 58285-0010WO1whereinis the point of attachment to the antibiotic, optionally whereinis the point of attachment to an -NH2, -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, andis the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;LAis a bond„ LBis a bondindicates the point of attachment t(7) is selected from phenylene, pyridylene, thiazolylene, and triazolylene;Y is absent, -NR3-CH2CH2-NR4-C(O)-, or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein an R7is attached to the pyridylene;R1and R2are independently selected from hydrogen and C1-C6 alkyl;R3and R4are independently selected from hydrogen and C1-C6 alkyl;R5and R6are independently selected from hydrogen and C1-C6 alkyl;R7is hydrogen or -(C1-C6 alkylene)P-(O-CH2CH2)r-OR8;R8is selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;o is 0 or 1;p is 0 or 1;r is an integer from 1 to 20;K is Lysine or Arginine;Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, leucine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; andis the point of attachment to the covalent protein binding moiety.
16. The ADC of claim 15, wherein the self-immolative linker isAttorney Docket No. 58285-0010WO1 17. The ADC of claim 15, wherein the self-immolative linker is19. The ADC of claim 15 or 16, wherein the self-immolative linker is21. The ADC of any one of claims 15 to 19, wherein K is arginine.
22. The ADC of any one of claims 15 to 19, wherein K is lysine.
23. The ADC of any one of claims 15 to 22, wherein Z is valine.
24. The ADC of any one of claims 15 to 22, wherein Z is serine.Attorney Docket No. 58285-0010WO125. The ADC of any one of claims 15 to 24, wherein the covalent protein binding moietyis selected from the group consistingwherein ‘" ” jsthe point of attachment to Z of the self-immolative linker;indicates the point of attachment to a cysteine residue of the antibody; andn and m is an integer from 1-20.
26. The ADC of any one of claims 15 to 24, wherein the covalent protein binding moiety, ” is the point of attachment to Z of the self-immolative linker;“*’■ indicates the point of attachment to a cysteine residue of the antibody; and wherein n is 5.
27. The ADC of any one of claims 1 to 14, wherein the ADC comprises the structure:(Formula XIV),wherein Q is 1 to 14, wherein the drug is the antibiotic.
28. The ADC of any one of claims 1 to 14, wherein the ADC comprises the structure:Attorney Docket No. 58285-0010WO1(Formula XV),wherein Q is 1 to 14, wherein the drug is the antibiotic.
29. The ADC of any one of claims 1 to 14, wherein the ADC comprises the structure:(Formula XVI)wherein Q is 1 to 14. wherein the drug is the antibiotic; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
30. The ADC of any one of claims 1 to 14, wherein the ADC comprises the structure:(Formula XVII)wherein Q is 1 to 14, wherein the drug is the antibiotic; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO131. The ADC of any one of claims 1 to 30, wherein the antibiotic treats a gram-negative bacterial infection.
32. The ADC of any one of claims 1 to 30, wherein the antibiotic treats a gram-positive bacterial infection.
33. The ADC of any one of claims 1 to 30, wherein the antibiotic is a fluoroquinolone.
34. The ADC of any one of claims 1 to 30, wherein the antibiotic is sitafloxacin.
35. The ADC of any one of claims 1 to 30, wherein the antibiotic is moxifloxacin.
36. The ADC of any one of claims 1 to 30, wherein the antibiotic is amoxicillin.
37. The ADC of any one of claims 1 to 30, wherein the antibiotic is metronidazole (MTZ).
38. The ADC of any one of claims 1 to 14, comprisingwherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
39. The ADC of any one of claims 1 to 14, comprisingIllAttorney Docket No. 58285-0010WO1wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
40. The ADC of any one of claims 1 to 14, comprisingwherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
41. The ADC of any one of claims 1 to 14, comprisingwherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO142. The ADC of any one of claims 1 to 14, comprisingQ,wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
43. The ADC of any one of claims 1 to 14, comprisingQ,wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
44. The ADC of any one of claims 1 to 14, comprisingAttorney Docket No. 58285-0010WO1wherein Q is 1 to 14, optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
45. The ADC of any one of claims 27-44, wherein Q is 1.
46. The ADC of any one of claims 27-44, wherein Q has a value from 3 to 5.
47. The ADC of claim 1, wherein the antibiotic is metronidazole, and wherein the ADC comprises:wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
48. The ADC of claim 1, wherein the antibiotic is metronidazole, and wherein the ADC comprises:Attorney Docket No. 58285-0010WO1Q,wherein Q is 1 to 14. wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
49. The ADC of claim 1. wherein the antibiotic is metronidazole, and wherein the ADC comprises:wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO150. The ADC of claim 1, wherein the antibiotic is amoxicillin, and wherein the ADC comprises:wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
51. The ADC of claim 1, wherein the antibiotic is sitafloxacin, and wherein the ADC comprises:wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
52. The ADC of claim 1, wherein the antibiotic is moxifloxacin, and wherein the ADC comprises:Attorney Docket No. 58285-0010WO1Q,wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO: 30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
53. The ADC of claim 1. wherein the antibiotic is sitafloxacin, and wherein the ADC comprises:wherein Q is 1 to 14, wherein the VH comprises the sequence of SEQ ID NO:30 and the VL comprises the sequence of SEQ ID NO:33; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO154. The ADC of claim 1, wherein the antibiotic is metronidazole, and wherein the ADC comprises:wherein Q is 1 to 14, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
55. The ADC of claim 1, wherein the antibiotic is metronidazole, and wherein the ADC comprises:Q,wherein Q is 1 to 14, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO156. The ADC of claim 1, wherein the antibiotic is metronidazole, and wherein the ADC comprises:wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
57. The ADC of claim 1, wherein the antibiotic is amoxicillin, and wherein the ADC comprises:wherein Q is 1 to 14, wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
58. The ADC of claim 1, wherein the antibiotic is sitafloxacin, and wherein the ADC comprises:Attorney Docket No. 58285-0010WO1Q,wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
59. The ADC of claim 1. wherein the antibiotic is moxifloxacin, and wherein the ADC comprises:Q,wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.Attorney Docket No. 58285-0010WO160. The ADC of claim 1, wherein the antibiotic is sitafloxacin, and wherein the ADC comprises:wherein Q is 1 to 14. wherein the antibody is an immunoglobulin comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:263 and the light chain comprises the sequence of SEQ ID NO:253; optionally wherein Q is 1 to 8, optionally wherein Q is 3 to 5.
61. A pharmaceutical composition, comprising the ADC of any one of claims 1 to 60, and a pharmaceutically acceptable carrier.
62. A linker-payload comprising: a linker comprising a covalent protein binding moiety and a self-immolative linker comprising (i) a lysine or arginine, and (ii) a payload, wherein the payload is an antibiotic; wherein(a) the self-immolative linker isis the point of attachment to the antibiotic, optionally whereinis the point of attachment to an -NH2. -NH-, or a hydroxy of the antibiotic, wherein the antibiotic comprises an -NH2, -NH-, or a hydroxy, andis the point of attachment to the -NH2, -NH-, or the hydroxy of the antibiotic;LAis a bondLBis a bondhere indicates the point of attachment toselected from phenylene, thiazolylene, and triazolylene;Attorney Docket No. 58285-0010WO1Y is absent, -NR3-CH2CH2-NR4-C(O)-, or -NR5-(CH2)o-pyridylene-NR6-C(O)-, wherein R7is attached to the pyridylene;R1and R2are independently selected from hydrogen and C1-C6 alkyl;R3and R4are independently selected from hydrogen and C1-C6 alkyl;R5and R6are independently selected from hydrogen and C1-C6 alkyl;R7is hydrogen or -(C1-C6 alkylene)p-(O-CH2CH2)r-OR8;R8is selected from hydrogen and C1-C6 alkyl optionally substituted with hydroxy;o is 0 or 1;p is 0 or 1;r is an integer from 1 to 20;K is Lysine or Arginine;Z is an amino acid, optionally wherein Z is serine, valine, asparagine, glycine, alanine, or other small, polar, or acidic amino acid, optionally wherein Z is serine or valine; andis the point of attachment to the covalent protein binding moiety; and(b) the covalent protein binding moiety is selected from the group consisting of” is the point of attachment to Z of the self-immolative linker;indicates the point of attachment to a cysteine residue of the antibody; andn and m is an integer from 1-20.
63. An antibody drug-conjugate (ADC) comprising the linker-payload of claim 62.
64. A pharmaceutical composition comprising the ADC of claim 63 and a pharmaceutically acceptable carrier.
65. A method of making the ADC of any one of claims 1 to 60 and 63, the method comprising (a) culturing a cell producing the antibody, (b) isolating the antibody, (c) reducing the isolated antibody, and (c) conjugating the reduced, isolated antibody to the linker comprising the covalent protein binding moiety, the self-immolative linker comprising a lysine or arginine, and an antibiotic; optionally wherein the method further comprises formulating the ADC as a sterile pharmaceutical composition.Attorney Docket No. 58285-0010WO166. A method of treating aP. gingivalis infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of claims 1 to 60 and 63; and optionally wherein the subject is a human.
67. A method of treating a condition, disorder, or disease associated with aP. gingivalis infection, or symptoms thereof, in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of claims 1 to 60 and 63; optionally wherein the condition, disorder, or disease associated with a P. gingivalis infection is peri-implantitis, periodontal disease, bone loss associated with periodontal disease, an age-related cognitive disorder, or a longevity- or age-related disorder; and optionally wherein the subject is a human.
68. A method of treating peri-implantitis, periodontal disease, or bone loss associated with periodontal disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of claims 1 to 60 and 63, wherein the subject has aP. gingivalis infection, and optionally wherein the subject is a human.
69. A method of treating age-related cognitive disorder, or a longevity- or age-related disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of claims 1 to 60 and 63, wherein the subject has aP. gingivalis infection, and optionally wherein the subject is a human, optionally wherein the age-related cognitive disorder is a dementia or Alzheimer’s disease.
70. A method of treating a systemic inflammatory disease associated with periodontitis or associated with aP. gingivalis infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the ADC of any one of claims 1 to 60 and 63, wherein the subject has aP. gingivalis infection, and optionally wherein the subject is a human, optionally wherein the systemic inflammatory disease associated with periodontitis or associated with aP. gingivalis infection is a dementia, Alzheimer's disease, a cognitive disorder, or heart disease.Attorney Docket No. 58285-0010WO171. A method of delivering an antibiotic to a subject in need thereof, the method comprising administering to the subject the ADC of any one of claims 1 to 60 and 63, optionally wherein the subject is a human.
